[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 235
1. Cagayan MS, Lu-Lasala LR: Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital. J Reprod Med; 2006 Oct;51(10):785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital.
  • Of the 30 patients, 17 (56.7%) belonged to the "early" group (having central nervous system [CNS] symptoms on presentation), while 13 (43.3%) were in the "late" group (individuals who developed lesions during chemotherapy or who had relapsed after initial complete or partial remission).
  • The mean survival time for the early CNS group was 7.3 months; it was 8.3 months for the late CNS group.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Gestational Trophoblastic Disease / epidemiology. Uterine Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Injections, Spinal. Medical Records. Methotrexate / administration & dosage. Middle Aged. Neoplasm Metastasis. Philippines / epidemiology. Pregnancy. Retrospective Studies. Survival Analysis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17086807.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; EMA-CO protocol
  •  go-up   go-down


2. Roche FP, Sheahan BJ, O'Mara SM, Atkins GJ: Semliki Forest virus-mediated gene therapy of the RG2 rat glioma. Neuropathol Appl Neurobiol; 2010 Dec;36(7):648-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Glioblastoma multiforme is the most common and most malignant adult brain tumour.
  • We examined the Semliki Forest virus virus-like particle (SFV VLP) expression system encoding interleukin-12 (IL-12) as a therapeutic intervention against the syngeneic RG2 rat glioma model.
  • High-dose treatment resulted in an 87% reduction in tumour volume, related to the oncolytic capacity of the SFV VLP system.
  • VLP delivery to the central nervous system (CNS) demonstrated the potential of the vector system to induce lethal pathology that was unrelated to replication-competent virus or high-level IL-12 expression.
  • CONCLUSION: The efficacy of an IL-12 gene therapy approach for the treatment of the RG2 glioma model has been demonstrated in addition to the oncolytic capacity of the VLP vector system.
  • Despite this, the broad tropism of the SFV-based expression vector may limit use as a CNS gene therapy vector unless this inherent limitation can be overcome.
  • [MeSH-major] Brain Neoplasms / therapy. Genetic Therapy / methods. Glioma / therapy. Semliki forest virus / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Endpoint Determination. Interleukin-12 / biosynthesis. Interleukin-12 / genetics. Kaplan-Meier Estimate. Male. Neoplasm Transplantation. Rats. Rats, Inbred F344. Stereotaxic Techniques. Virus Replication

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Neuropathology and Applied Neurobiology © 2010 British Neuropathological Society.
  • (PMID = 20649937.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12
  •  go-up   go-down


3. Schrøder H, Kjeldahl M, Boesen AM, Nielsen OJ, Schmidt K, Johnsen HE, Gregersen H, Heyman M, Gustafsson G: Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication. Dan Med Bull; 2006 Feb;53(1):76-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Data seem to indicate that young adults with acute lymphoblastic leukemia (ALL) have a better survival when treated with pediatric protocols compared with adult ALL protocols.
  • RESULTS: There were no difference with respect to the distribution of T-ALL, CNS-leukemia, total white blood count and high risk chromosomal abnormalities between the two groups.
  • CONCLUSION: Young adult patients with ALL might benefit from therapy with pediatric NOPHO ALL protocols.
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Stem Cell Transplantation. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761337.001).
  • [ISSN] 1603-9629
  • [Journal-full-title] Danish medical bulletin
  • [ISO-abbreviation] Dan Med Bull
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


Advertisement
4. Tzika AA, Astrakas L, Cao H, Mintzopoulos D, Andronesi OC, Mindrinos M, Zhang J, Rahme LG, Blekas KD, Likas AC, Galatsanos NP, Carroll RS, Black PM: Combination of high-resolution magic angle spinning proton magnetic resonance spectroscopy and microscale genomics to type brain tumor biopsies. Int J Mol Med; 2007 Aug;20(2):199-208
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of high-resolution magic angle spinning proton magnetic resonance spectroscopy and microscale genomics to type brain tumor biopsies.
  • Advancements in the diagnosis and prognosis of brain tumor patients, and thus in their survival and quality of life, can be achieved using biomarkers that facilitate improved tumor typing.
  • We introduce and implement a combinatorial metabolic and molecular approach that applies state-of-the-art, high-resolution magic angle spinning (HRMAS) proton (1H) MRS and gene transcriptome profiling to intact brain tumor biopsies, to identify unique biomarker profiles of brain tumors.
  • The MRS and genomic analyses demonstrate that CNS tumors have altered levels of specific 1H MRS metabolites that directly correspond to altered expression of Kennedy pathway genes; and exhibit rapid phospholipid turnover, which coincides with upregulation of cell proliferation genes.
  • Our combined metabolic/molecular MRS/genomic approach provides insights into the biology of anaplastic ganglioglioma and a new potential tumor typing methodology that could aid neurologists and neurosurgeons to improve the diagnosis, treatment, and ongoing evaluation of brain tumor patients.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Genomics / methods. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy / methods. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Biopsy. Cluster Analysis. Feasibility Studies. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Models, Biological. Oligonucleotide Array Sequence Analysis. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611638.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


5. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss D, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine P, Medina LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study. Head Neck; 2005 Jun;27(6):445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study.
  • BACKGROUND: Advances in imaging, surgical technique, and perioperative care have made craniofacial resection (CFR) an effective and safe option for treating malignant tumors involving the skull base.
  • Because of the relative rarity of these tumors, most existing data on postoperative complications come from individual reports of relatively small series of patients.
  • This international collaborative report examines a large cohort of patients accumulated from multiple institutions with the aim of identifying patient-related and tumor-related predictors of postoperative morbidity and mortality and set a benchmark for future studies.
  • Postoperative complications were classified into systemic, wound, central nervous system (CNS), and orbit.
  • Wound complications occurred in 237 (19.8%), CNS-related complications in 193 (16.2%), orbital complications in 20 (1.7%), and systemic complications in 57 (4.8%) patients.
  • CONCLUSIONS: CFR is a safe surgical treatment for malignant tumors of the skull base, with an overall mortality of 4.7% and complication rate of 36.3%.
  • The impact of medical comorbidity and intracranial tumor extent should be carefully considered when planning therapy for patients whose tumors are amenable to CFR.
  • [MeSH-major] Postoperative Complications. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. International Cooperation. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 15825205.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


6. Eyenga VC, Ngah JE, Atangana R, Etom E, Ngowe MN, Bassong Y, Oyono JL, Sosso M: [Central nervous system tumours in Cameroon: histopathology and demography]. Sante; 2008 Jan-Mar;18(1):39-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central nervous system tumours in Cameroon: histopathology and demography].
  • [Transliterated title] Les tumeurs du système nerveux central au Cameroun: histopathologie, démographie.
  • Tumours of the central nervous system (CNS) have not received much scientific attention in sub-Saharan Africa, especially in the central African zone.
  • The aim of this study was to determine the relative frequency and different histologic types of CNS tumours seen in the neurosurgery units of Cameroon, a multiethnic country of central Africa.
  • This retrospective study covers the decade from January 1996 through December 2006 in the three neurosurgery departments in Cameroon, at the Yaoundé General Hospital, the Yaoundé Central Hospital, and the Douala General Hospital.
  • INCLUSION CRITERIA: All cases undergoing surgery in these units for a histologically-confirmed CNS tumour.
  • The average age of patients with metastatic tumors was 42+/-18.5 years compared with 36.5+/-17.8 years for cases with primary tumors.
  • Primary tumors were malignant in 34.2% (n=12) of the children and benign in 65.8% (n=23); among adults 22.7% (n=30) were malignant and 77.3% (n=102) benign.
  • In conclusion, CNS tumors occurred mainly before the age of 55 years and had a slight predilection for girls and women.
  • Meningiomas were the most frequent tumors in adults while astrocytomas were more prevalent in children.
  • [MeSH-major] Brain Neoplasms / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / epidemiology. Astrocytoma / pathology. Brain / pathology. Cameroon. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Meninges / pathology. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684690.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Arshad H, Ahmad Z, Hasan SH: Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev; 2010;11(6):1637-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grade is the most significant prognostic factor determining survival, but various proliferation markers are being increasingly employed by histopathologists as adjuncts to conventional morphologic variables to determine prognostic behavior of brain tumors.
  • OBJECTIVE: To correlate World Health Organization (WHO) grades of glial neoplasms and expression of MIB1 and P53 by these tumors with patient survival at the end of one year.
  • MATERIAL AND METHODS: 50 consecutive cases with confirmed diagnosis of various histologic types of glial neoplasms were included.
  • Grading was done according to the WHO grading system for CNS neoplasms.
  • CONCLUSION: Histologic grade is the most important prognostic factor with respect to patient survival in glial neoplasms.
  • Immunohistochemical staining with MIB1 and p53 may serve as an additional useful toolin determining the clinical course in combination with and as an adjunct to tumor grade.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Glioma / metabolism. Glioma / mortality. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21338209.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


8. Rezanko T, Tunakan M, Kahraman A, Sucu HK, Gelal F, Akkol I: Primary rhabdoid tumor of the brain in an adult. Neuropathology; 2006 Feb;26(1):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rhabdoid tumor of the brain in an adult.
  • Rhabdoid tumor (RT) is an uncommon childhood neoplasm that typically arises within the kidney.
  • Since its description in 1978, several cases of primary extrarenal RT, including a CNS localization, have been reported.
  • The first case in the CNS was reported in 1985 and was defined as "rhabdoid tumor" initially, and was classified as grade IV in the most recent classification of the World Health Organization under the term of "atypical teratoid/rhabdoid tumor".
  • Nearly 200 cases of atypical teratoid/rhabdoid tumor of the CNS have been reported to date, most of them occurring in childhood.
  • This tumor, which was composed purely of rhabdoid cells with no additional primitive neuroectodermal, epithelial and mesenchymal components, was in a 27-year-old male patient.
  • In conclusion, RT should be considered also in the differential diagnosis of intracerebral neoplasms of adult patients.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Meningioma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521480.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Daood M, Tsai C, Ahdab-Barmada M, Watchko JF: ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics; 2008 Aug;39(4):211-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
  • Little is known about the neonatal and developmental expression of P-gp/ABCB1, MRP1/ABCC1, and BCRP/ABCG2 in the human central nervous system (CNS), therefore post-mortem CNS tissue from infants born at 22 (0/7)-42 (0/7) weeks of gestation and adults was immunostained to determine their ontogeny and cellular localization.
  • P-gp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2 in adult brain matched term newborn CNS but with more intense immunostaining.
  • We conclude that P-gp/ABCB1, MRP1/ABCC1, and BCRP/ABCG2 are expressed in a developmental, cell specific, fashion in the human CNS.
  • The complementary pattern of P-gp/ABCB1 and BCRP/ABCG2 at the blood-brain with MRP1/ABCC1 at the blood-CSF barriers may limit CNS uptake and retention of drugs and toxins in neonates.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Central Nervous System / growth & development. Central Nervous System / metabolism. Multidrug Resistance-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family B. ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adult. Female. Gene Expression Regulation, Developmental. Humans. Infant, Newborn. Male. Postmortem Changes

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 2000 Jun 1;60(5):594-601 [10820430.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5269-77 [11016657.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1469-76 [11245453.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):1064-8 [11689020.001]
  • [Cites] J Neural Transm Suppl. 2001;(61):35-45 [11771758.001]
  • [Cites] Biol Neonate. 2002 Jan;81(1):58-64 [11803178.001]
  • [Cites] J Perinatol. 2001 Dec;21 Suppl 1:S43-7; discussion S59-62 [11803416.001]
  • [Cites] Brain. 2002 Jan;125(Pt 1):22-31 [11834590.001]
  • [Cites] J Pathol. 2002 Oct;198(2):213-9 [12237881.001]
  • [Cites] Neuroreport. 2002 Nov 15;13(16):2059-63 [12438926.001]
  • [Cites] J Histochem Cytochem. 2002 Dec;50(12):1671-6 [12486090.001]
  • [Cites] Neuroscience. 2003;118(2):417-29 [12699778.001]
  • [Cites] Dev Growth Differ. 2003 Aug;45(4):377-87 [12950279.001]
  • [Cites] FASEB J. 2003 Nov;17(14):2085-7 [12958161.001]
  • [Cites] Neuroscience. 2004;123(3):751-9 [14706787.001]
  • [Cites] Pediatr Neurol. 2004 Feb;30(2):102-6 [14984901.001]
  • [Cites] Cell Mol Neurobiol. 2004 Feb;24(1):101-7 [15049514.001]
  • [Cites] Trends Mol Med. 2004 Feb;10(2):65-70 [15102359.001]
  • [Cites] Neuroscience. 2004;129(2):349-60 [15501592.001]
  • [Cites] J Neurochem. 1976 Aug;27(2):577-83 [966000.001]
  • [Cites] Differentiation. 1983;25(2):193-203 [6198232.001]
  • [Cites] J Neuropathol Exp Neurol. 1984 Jan;43(1):45-56 [6693927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8 [2563168.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):152-6 [1688652.001]
  • [Cites] Sel Cancer Ther. 1991 Summer;7(2):49-58 [1721722.001]
  • [Cites] Am J Pathol. 1992 Nov;141(5):1063-72 [1359789.001]
  • [Cites] Biochim Biophys Acta. 1993 Aug 15;1150(2):147-54 [8102251.001]
  • [Cites] Am J Pathol. 1994 Feb;144(2):227-36 [7508682.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1237-47 [8644864.001]
  • [Cites] Vet Pathol. 1996 Sep;33(5):533-41 [8885180.001]
  • [Cites] Acta Neuropathol. 1997 May;93(5):450-60 [9144583.001]
  • [Cites] Histochem Cell Biol. 1997 Aug;108(2):179-82 [9272437.001]
  • [Cites] Biochem J. 1997 Sep 1;326 ( Pt 2):539-44 [9291129.001]
  • [Cites] Neuroimage. 1994 Nov;1(4):276-87 [9343577.001]
  • [Cites] J Neurochem. 1998 Mar;70(3):1151-9 [9489736.001]
  • [Cites] J Neurochem. 1998 Aug;71(2):705-15 [9681461.001]
  • [Cites] Pediatr Res. 1998 Nov;44(5):763-6 [9803459.001]
  • [Cites] Brain Res. 1999 Feb 20;819(1-2):143-6 [10082869.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3900-5 [10097135.001]
  • [Cites] J Neurobiol. 1999 Jun 5;39(3):383-92 [10363911.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37 [15845415.001]
  • [Cites] Epilepsia. 2005 Jun;46(6):849-57 [15946326.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Feb;32(1):51-63 [16409553.001]
  • [Cites] Drug Metab Dispos. 2006 Feb;34(2):288-95 [16303871.001]
  • [Cites] J Histochem Cytochem. 2006 Oct;54(10):1159-67 [16801529.001]
  • [Cites] J Neurol Sci. 2007 Jul 15;258(1-2):84-92 [17459414.001]
  • [Cites] Seizure. 2007 Sep;16(6):493-503 [17482840.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):50-61 [18091560.001]
  • (PMID = 19165709.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS038993-07; United States / NINDS NIH HHS / NS / R01 NS038993-08; United States / NINDS NIH HHS / NS / NS 38993
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; Y49M64GZ4Q / multidrug resistance-associated protein 1
  • [Other-IDs] NLM/ NIHMS174607; NLM/ PMC2821654
  •  go-up   go-down


10. Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM: Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line. J Neurooncol; 2007 Aug;84(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas are the most common and devastating primary tumors of the adult central nervous system.
  • Dexamethasone, a synthetic glucocorticoid, is commonly co-administered to control edema in the management of brain tumors during chemotherapy and radiotherapy.
  • [MeSH-major] 5'-Nucleotidase / metabolism. Anti-Inflammatory Agents / pharmacology. Brain Neoplasms / enzymology. Dexamethasone / pharmacology. Glioma / enzymology
  • [MeSH-minor] Adenosine Monophosphate / metabolism. Animals. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Protein Kinase C / metabolism. Purines / metabolism. Rats. Signal Transduction / drug effects. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):805-9 [8687132.001]
  • [Cites] Anal Biochem. 1986 Sep;157(2):375-80 [2946250.001]
  • [Cites] Am J Reprod Immunol. 2005 Mar;53(3):144-52 [15727569.001]
  • [Cites] Vascul Pharmacol. 2005 Mar;42(4):153-62 [15820441.001]
  • [Cites] J Cell Physiol. 2001 Jan;186(1):19-23 [11147810.001]
  • [Cites] J Neurooncol. 2001 Jan;51(2):105-10 [11386406.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] Drug Metab Dispos. 2006 Jun;34(6):1063-9 [16531474.001]
  • [Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]
  • [Cites] Pharmacol Ther. 2003 Oct;100(1):31-48 [14550503.001]
  • [Cites] Neurology. 1997 Jun;48(6):1704-9 [9191791.001]
  • [Cites] Purinergic Signal. 2006 Jun;2(2):409-30 [18404480.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4A):1585-8 [7979189.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Dec;92(5):375-82 [15698542.001]
  • [Cites] Eur J Pharmacol. 1992 Oct 1;227(2):113-22 [1426027.001]
  • [Cites] Br J Pharmacol. 1997 Jan;120(2):273-81 [9117120.001]
  • [Cites] J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43 [16125621.001]
  • [Cites] Genes Dev. 1995 Jul 1;9(13):1608-21 [7628695.001]
  • [Cites] Neuroscience. 2000;96(2):417-25 [10683582.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4472-8 [12947007.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R25-32 [11124130.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1567-75 [9794234.001]
  • [Cites] Trends Pharmacol Sci. 2006 Mar;27(3):166-76 [16487603.001]
  • [Cites] Apoptosis. 1999 Jun;4(3):197-211 [14634282.001]
  • [Cites] Melanoma Res. 2006 Jun;16(3):213-22 [16718268.001]
  • [Cites] BMC Cancer. 2006 Sep 23;6:226 [16995949.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Trends Pharmacol Sci. 2006 Apr;27(4):211-7 [16530853.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 25;20(4):825-9 [1531873.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):211-8 [12957360.001]
  • [Cites] Biochem J. 1992 Jul 15;285 ( Pt 2):345-65 [1637327.001]
  • (PMID = 17453149.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Purines; 415SHH325A / Adenosine Monophosphate; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.5 / 5'-Nucleotidase
  •  go-up   go-down


11. Grodman H, Wolfe L, Kretschmar C: Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatr Blood Cancer; 2009 Jul;53(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
  • BACKGROUND: Adults and children with recurrent malignant central nervous system (CNS) tumors have a poor prognosis despite high dose chemotherapy with a conventional stem cell rescue regimen.
  • In this study we evaluated the results of low dose, continuous infusion etoposide over 21 days added to a conventional high-dose regimen of carboplatin and thiotepa in eight patients with relapsed pediatric CNS tumors.
  • PROCEDURE: Patients with high risk CNS tumors were treated with etoposide 25 mg/m(2)/day by continuous intravenous (IV) infusion from day -22 to day -2, carboplatin 667 mg/m(2)/dose IV (or area under the curve = 9 mg/ml/min according to the Calvert formula on days -8, -7, and -6, and thiotepa 300 mg/m(2)/dose IV on days -5, -4, and -3, followed by autologous hematopoietic stem cell rescue on day 0.
  • RESULTS: Eight adults and children, with a mean age of 12.9 years (age range 5.6-27.8 years), with relapsed primary CNS tumors (metastatic medulloblastoma (7), germinoma (1)), were enrolled.
  • This treatment strategy deserves further evaluation in a larger group of high-risk or relapsed primary CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Etoposide / administration & dosage. Germinoma / therapy. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Adult. Anemia / chemically induced. Anemia / therapy. Carboplatin / administration & dosage. Child. Child, Preschool. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / therapy. Humans. Infusions, Intravenous. Male. Survival Rate. Thiotepa / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19326417.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E, Colleoni M: Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer; 2006;6:225
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic sites included: lung (5 pts), liver (14 pts), bone (12 pts), lymph nodes (8 pts), central nervous system (CNS) (9 pts).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Genes, erbB-2. Immunization, Passive. Neoplasm Proteins / antagonists & inhibitors. Receptor, ErbB-2 / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bone Neoplasms / blood supply. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Brain Neoplasms / blood supply. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Drug Administration Schedule. Female. Gene Amplification. Humans. Leukopenia / chemically induced. Liver Neoplasms / blood supply. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / blood supply. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Lymphatic Metastasis. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neutropenia / chemically induced. Remission Induction. Trastuzumab. Treatment Outcome. Ventricular Dysfunction, Left / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1248-57 [10882863.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):904-16 [16467105.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2722-30 [11352965.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3995-4004 [11359907.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):73-80 [11863115.001]
  • [Cites] Nature. 2002 Mar 21;416(6878):279-80 [11907566.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1800-8 [11919237.001]
  • [Cites] Mol Biol Cell. 2002 Nov;13(11):4029-44 [12429844.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1673-80 [12820439.001]
  • [Cites] Clin Breast Cancer. 2003 Jun;4(2):120-5 [12864940.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1377-85 [14508823.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1063-70 [15020607.001]
  • [Cites] Clin Breast Cancer. 2004 Apr;5(1):52-8; discussion 59-62 [15140285.001]
  • [Cites] Nature. 1986 Jan 16-22;319(6050):226-30 [3945311.001]
  • [Cites] Nature. 1986 Jan 16-22;319(6050):230-4 [3003577.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):832-9 [3755076.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Oncology (Williston Park). 1997 Mar;11(3 Suppl 2):43-8 [9110342.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1523-30 [9403702.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2659-71 [9704716.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):791-808 [9797688.001]
  • [Cites] Clin Breast Cancer. 2005 Oct;6(4):325-9 [16277882.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):232-8 [16322118.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • (PMID = 16978400.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Neoplasm Proteins; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1579231
  •  go-up   go-down


13. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Jun 20;28(18):3069-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
  • Toxicities related to BVZ included grade 1 to 3 fatigue in seven patients, grade 1 to 2 hypertension in seven patients, grade 1 CNS hemorrhage in four patients, and grade 4 CNS ischemia in two patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Child. Diffusion Magnetic Resonance Imaging. Humans. Phosphorylation. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):309-16 [18337733.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):624-30 [18539884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9 [18793954.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):806-11 [18802947.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5598-605 [11114740.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2064-72 [11597385.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):6-17 [11840548.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):237-53 [12187958.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543 [12972536.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6 [15552623.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):172-87 [15687360.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2347-55 [15985545.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • (PMID = 20479404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01RR00188; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2903337
  •  go-up   go-down


14. Simon T, Kohlhase J, Wilhelm C, Kochanek M, De Carolis B, Berthold F: Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review. Am J Med Genet A; 2010 Jun;152A(6):1575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most remarkable clinical features are young age, spontaneous remission of diffuse large cell lymphoma, and severe CNS and skin toxicity of cytotoxic treatment.
  • [MeSH-major] Bone Neoplasms / genetics. Leukemia, Large Granular Lymphocytic / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Osteosarcoma / genetics. RecQ Helicases / genetics. Rothmund-Thomson Syndrome / genetics
  • [MeSH-minor] Fatal Outcome. Heterozygote. Humans. Male. Mutation. Neoplasm Regression, Spontaneous. Young Adult


15. Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R: A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest; 2005;23(4):303-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a site of frequent relapse is in the central nervous system (CNS).
  • Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Eye Neoplasms / drug therapy. Eye Neoplasms / mortality. Eye Neoplasms / pathology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Interleukin-2 / administration & dosage. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Skin Neoplasms / drug therapy. Skin Neoplasms / mortality. Skin Neoplasms / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100942.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA46934
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 85622-93-1 / temozolomide
  •  go-up   go-down


16. Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, Li J, Sohn T, Kim SH, Lubensky IA, Vortmeyer AO, Rodgers GP, Oldfield EH, Lonser RR: von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med; 2007 Feb;4(2):e60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To determine the origin of the neoplastic cell in central nervous system (CNS) hemangioblastomas in von Hippel-Lindau disease (VHL) and its role in tumor formation and distribution, we characterized and differentiated neoplastic cells from hemangioblastomas removed from VHL patients.
  • METHODS AND FINDINGS: A total of 31 CNS hemangioblastomas from 25 VHL patients were resected and analyzed.
  • Tumor cells from the hemangioblastomas were characterized, grown, and differentiated into multiple lineages.
  • Resected hemangioblastomas were located in the cerebellum (11 tumors), brainstem (five tumors), and spinal cord (15 tumors).
  • CONCLUSIONS: The neoplastic cell of origin for CNS hemangioblastomas in VHL patients is the mesoderm-derived, embryologically arrested hemangioblast.
  • These findings may also explain the unique tissue distribution of tumor involvement.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Hemangioblastoma / pathology. Multipotent Stem Cells / pathology. von Hippel-Lindau Disease / complications
  • [MeSH-minor] Adolescent. Adult. Antigens, CD13 / genetics. Blotting, Western. Cell Degranulation. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. RNA, Neoplasm / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured


17. Wolf RL, Wang J, Wang S, Melhem ER, O'Rourke DM, Judy KD, Detre JA: Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging; 2005 Oct;22(4):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla.
  • MATERIALS AND METHODS: CASL perfusion images were obtained preoperatively in 26 patients with brain neoplasms (19 high-grade gliomas (HGGs; WHO grades 3 and 4) and seven low-grade gliomas (LGGs; WHO grades 1 and 2)).
  • The mean and maximum tumor blood flow (TBF and TBFmax) were calculated in the neoplasm, including surrounding infiltrating tumor vs. edema.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Spin Labels

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161080.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS43381; United States / NINDS NIH HHS / NS / NS045839; United States / NCRR NIH HHS / RR / RR002305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Spin Labels
  •  go-up   go-down


18. Sharma MC, Ghara N, Jain D, Sarkar C, Singh M, Mehta VS: A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas. Neuropathology; 2009 Apr;29(2):148-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of proliferative markers and tumor suppressor gene proteins in different grades of ependymomas.
  • Ependymomas are CNS tumors that originate from the spinal canal and walls of the ventricular system.
  • Histopathologic grades show relationship with MIB1 and Topo IIalpha labelling indices and cut-off values of 5% can differentiate between anaplastic and lower grades. p53 and MDM2 proteins expression are not common in ependymomas; however, they are seen in higher grades only and may be involved in the tumor progression.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. DNA Topoisomerases, Type II / metabolism. Ependymoma / metabolism. Ependymoma / pathology. Ki-67 Antigen / metabolism. Proto-Oncogene Proteins c-mdm2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721229.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


19. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


20. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK, Cintredekin Besudotox Intraparenchymal Study Group: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol; 2007 Mar 1;25(7):837-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Glioblastoma multiforme (GBM) is a devastating brain tumor with a median survival of 6 months after recurrence.
  • PATIENTS AND METHODS: Three phase I clinical studies evaluated intracerebral CED of CB along with tumor resection.
  • All patients underwent tumor resection followed by a single intraparenchymal infusion (in addition to the intraparenchymal one following resection), with a portion of patients who had a preresection intratumoral infusion.
  • The maximum tolerated intraparenchymal concentration was 0.5 microg/mL and tumor necrosis was observed at this concentration.
  • CB- and procedure-related adverse events were primarily limited to the CNS.
  • [MeSH-major] Drug Delivery Systems / methods. Exotoxins / administration & dosage. Glioma / drug therapy. Immunotoxins / administration & dosage. Interleukin-13 / administration & dosage. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Catheterization. Convection. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Tissue Distribution

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327604.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13
  •  go-up   go-down


21. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol; 2007 Feb 1;25(4):399-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
  • PURPOSE: This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain tumors, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.
  • Tumor samples were evaluated for AGT levels.
  • Future trials are required to determine if the inhibition of tumor AGT levels results in increased efficacy.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • (PMID = 17264335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256
  •  go-up   go-down


22. Rothman J, Greenberg RE, Jaffe WI: Nonseminomatous germ cell tumor of the testis 9 years after a germ cell tumor of the pineal gland: case report and review of the literature. Can J Urol; 2008 Jun;15(3):4122-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonseminomatous germ cell tumor of the testis 9 years after a germ cell tumor of the pineal gland: case report and review of the literature.
  • Extragonadal germ cell tumors are extremely rare and account for only 3%-5% of all germ cell tumors.
  • These tumors are rarely associated with metachronous primary testicular germ cell tumors.
  • We report the fourth case of a primary germ cell tumor occurring after the treatment of a primary CNS germ cell tumor in a 27 year-old male with embryonal cell carcinoma of the testicle 9 years after the treatment of a germ cell tumor of the pineal gland.
  • This represents the first case of a non-seminomatous germ cell tumor of the testicle after a CNS germ cell tumor.
  • This case illustrates the importance of long term follow-up and self-examination in patients with extragonadal germ cell tumors.
  • [MeSH-major] Brain Neoplasms. Carcinoma, Embryonal. Neoplasms, Germ Cell and Embryonal. Neoplasms, Second Primary. Pineal Gland. Testicular Neoplasms
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Recurrence, Local


23. Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, Korfel A: Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol; 2006 Jul;17(7):1141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective trial on topotecan salvage therapy in primary CNS lymphoma.
  • BACKGROUND: Standard salvage therapy has not been established for recurrent primary central nervous system lymphoma (PCNSL).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603598.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


24. Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A, German Primary Central Nervous System Lymphoma Study Group: Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol; 2006 Nov;80(2):159-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.
  • Data on relapsed primary central nervous system lymphoma (PCNSL) are limited.
  • Forty-four of 51 evaluable patients relapsed within the CNS, 6 systemically and one both cerebrally and systemically.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Karnofsky Performance Status. Male. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Prognosis. Salvage Therapy. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):339-45 [9031115.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):530-4 [10027325.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):519-26 [10653867.001]
  • [Cites] Br J Haematol. 2005 Jan;128(2):177-83 [15638851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1157-62 [9539572.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Ann Intern Med. 1993 Dec 1;119(11):1093-104 [8239229.001]
  • [Cites] Ann Neurol. 2002 Feb;51(2):247-52 [11835382.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):663-73 [7558957.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):445-9 [15653703.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B113-7 [11757691.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4483-8 [14597741.001]
  • [Cites] Eur J Haematol. 1998 Jul;61(1):59-64 [9688294.001]
  • [Cites] J Neurooncol. 1996 Dec;30(3):257-65 [8943101.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 16699873.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
  • OBJECTIVE: To study clinicopathologic features, diagnosis, treatment and prognosis of von Hippel-Lindau (VHL) syndrome-related and sporadic hemangioblastomas of the central nervous system (CNS-HB).
  • METHODS: Histopathological, ultrastructural, immunohistochemical (EnVision method) and clinical features of 21 VHL syndrome and 63 sporadic CNS-HB cases were studied with correlation of the available follow-up information.
  • RESULTS: Twenty-one VHL patients accompanied with a total of 87 CNS-HBs, including one patient of developing 12 HBs within 13 years.
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • In the 63 cases of sporadic CNS-HB (34 male and 29 female), the mean age was 43.0 years.
  • Histologically, the tumors showed large and vacuolated stromal cells.
  • Some tumors showed atypical nuclei.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • Prognosis of CNS-HB patients is not correlated with the nuclear atypicality, expression for Ki-67 and involvement of the brain tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


26. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
  • BACKGROUND: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children.
  • Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors.
  • RESULTS: The cohort comprised 122 patients, including 113 with CNS tumors.
  • Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


27. Fruchart C, Denoux Y, Chasle J, Peny AM, Boute V, Ollivier JM, Genot JY, Michels JJ: High grade primary breast lymphoma: is it a different clinical entity? Breast Cancer Res Treat; 2005 Oct;93(3):191-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary lymphoma of the breast (PBL) is a rare neoplasm, its outcome remains unclear compared to other lymphomas.
  • Three patients progressed on therapy and 5 relapsed in the first year of follow-up including 2 central nervous system recurrences.
  • The treatment should be based on the same modalities, but including a CNS prophylaxis even if poor prognosis factors are lacking.
  • [MeSH-major] Breast Neoplasms. Lymphoma, Follicular. Lymphoma, Large B-Cell, Diffuse
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. France / epidemiology. Humans. Immunophenotyping. Lymphoma, B-Cell, Marginal Zone / pathology. Middle Aged. Neprilysin / metabolism. Prognosis. Proto-Oncogene Proteins c-bcl-6 / metabolism. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172797.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-6; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


28. Mohile NA, Deangelis LM, Abrey LE: The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol; 2008 Apr;10(2):223-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of body FDG PET in staging primary central nervous system lymphoma.
  • (18)F-Fluorodeoxyglucose (FDG) PET has become an important tool in the management of non-Hodgkin's lymphoma (NHL), but its role in the evaluation of primary CNS lymphoma (PCNSL) has not been established.
  • NHL was found in 11% of all patients, 7% of patients at diagnosis, and 27% of patients at CNS relapse.
  • Four percent had a second systemic neoplasm.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma / pathology. Lymphoma / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):793-800 [11843811.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):325-9 [14647988.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):939-47 [2914300.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4643-51 [15837966.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4577-80 [15837974.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):611-27, v [16083826.001]
  • [Cites] Nucl Med Commun. 2006 Jan;27(1):11-5 [16340718.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] Haematologica. 2006 Apr;91(4):522-9 [16585017.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4754-7 [16966685.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):159-65 [16699873.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):11055-61 [17108145.001]
  • [Cites] Ann Hematol. 2007 Jan;86(1):9-15 [17021839.001]
  • [Cites] Br J Radiol. 2000 May;73(869):482-7 [10884743.001]
  • (PMID = 18287338.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2613825
  •  go-up   go-down


29. Weber C, Schaper J, Tibussek D, Adams O, Mackenzie CR, Dilloo D, Meisel R, Göbel U, Laws HJ: Diagnostic and therapeutic implications of neurological complications following paediatric haematopoietic stem cell transplantation. Bone Marrow Transplant; 2008 Feb;41(3):253-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Those with a progressive clinical course resulted from infections (n=10), drug toxicity (n=5), cerebrovascular events (n=2) and the central nervous system (CNS) relapse of the underlying disease (n=2).
  • In conclusion, our data suggest that patients presenting with progressive neurological symptoms after SCT require prompt diagnostic procedures and initiation in antimicrobial therapy in case of any findings suggestive of CNS infection.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Meningitis / etiology. Neoplasm Recurrence, Local. Neurotoxicity Syndromes / etiology. Seizures / etiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Female. Hospitals, Pediatric. Humans. Infant. Male. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982498.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Safwat A, Schmidt H, Bastholt L, Fode K, Larsen S, Aggerholm N, von der Maase H: A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. Radiother Oncol; 2005 Nov;77(2):143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The dose was modified in 15 cycles (26%) because of progression (6), liver toxicity (3), CNS toxicity (2), thrombocytopenia (1), lung morbidity (1) and itching (1).
  • [MeSH-major] Interleukin-2 / therapeutic use. Melanoma / secondary. Melanoma / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Whole-Body Irradiation / methods
  • [MeSH-minor] Adult. Aged. Denmark. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Flow Cytometry. Follow-Up Studies. Humans. Injections, Subcutaneous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Radiotherapy Dosage. Risk Assessment. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216360.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


31. Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nolè F: Brain metastases in patients with advanced breast cancer. Anticancer Res; 2007 Jul-Aug;27(4C):2865-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a case control study to define current features of breast cancer related to central nervous system (CNS) metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Cell Growth Processes / physiology. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis


32. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA: Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol; 2010 Aug;12(8):855-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
  • Grade 3/4 toxicities included leukopenia (n = 1), lymphopenia (n = 2), thrombocytopenia (n = 1), ALT elevation (n = 3), AST elevation (n = 1), CNS hemorrhage (n = 1), fatigue (n = 1), and thrombotic/embolic events (n = 3); 8 patients required dose reduction.
  • Two patients had a partial radiographic response by standard bidimensional measurements, whereas 9 patients (6 at the 8-week point and 3 only within the first month of treatment) had decreased contrast enhancement, vasogenic edema, and mass effect but <50% reduction in tumor.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrimidines / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neovascularization, Pathologic / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1083-93 [12651601.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(20):7748-52 [2845420.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5523-34 [15994924.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Cell Oncol. 2007;29(5):399-408 [17726262.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4659-65 [18824712.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35 [19037839.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] PLoS One. 2009;4(4):e5123 [19352490.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2542-52 [19332720.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3126-32 [19451427.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 [19167838.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • (PMID = 20200024.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00459381
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062421-12; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCRR NIH HHS / RR / M01RR03186; United States / NCI NIH HHS / CA / CA62399
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  • [Other-IDs] NLM/ PMC2940686
  •  go-up   go-down


33. Klabusay M, Pevná M, Kissová J, Doubek M, Heidekerová M, Mayer J, Vorlícek J: [Rare diagnosis of CD4+56+ leukemia from dendritic cells type DC2]. Cas Lek Cesk; 2008;147(10):511-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD4+56+ hematodermic neoplasm or leukemia from early plasmocytoid dendritic cells type DC2 was recognized by WHO-EORTC classification of cutaneous lymphomas as a separate entity related to the plasmacytoid precursor dendritic cell (pDC).
  • However, this aggressive disease requires radical approach with intensive chemotherapy regimens, prophylaxis of CNS involvement and early indication of allogeneic bone marrow transplantation.
  • [MeSH-major] Antigens, CD4 / analysis. Antigens, CD56 / analysis. Dendritic Cells / immunology. Leukemia / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177732.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56
  • [Number-of-references] 26
  •  go-up   go-down


34. O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS: Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol; 2009 Dec 20;27(36):6207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: One hundred thirty-three chemotherapy-naïve patients with metastatic melanoma without CNS metastases were treated at 10 melanoma centers.
  • Thirty-nine percent of patients developed CNS metastases.
  • The median times to CNS progression and death were 8 months and 5 months, respectively.
  • CNS progression remains a formidable challenge.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Interleukin-2 / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Remission Induction. Survival Analysis. Vinblastine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, Niitsu N, Miwa H, Asaoku H, Kosugi H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamamoto K, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T, IVL Study Group in Japan: Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci; 2010 Jun;101(6):1480-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.
  • Intravascular large B-cell lymphoma (IVLBCL) is a rare disease entity with a high incidence of central nervous system (CNS) involvement at diagnosis.
  • To evaluate CNS involvement, particularly recurrence including progression on therapy and relapse of IVLBCL, we retrospectively analyzed 109 patients with IVLBCL receiving chemotherapies with or without rituximab.
  • In 82 patients (75%) without CNS involvement at initial diagnosis, risk of CNS recurrence at 3 years was 25% with a median follow-up in survivors of 39 months (range, 2-158 months).
  • In 27 patients (25%) with CNS involvement at initial diagnosis, risk of CNS recurrence at 1 year was 25% with a median follow-up in survivors of 18 months (range, 10-77 months).
  • Duration from diagnosis to CNS recurrence tended to be short in patients with CNS involvement at diagnosis.
  • No significant difference in risk of CNS recurrence was found between patients receiving chemotherapies with or without rituximab.
  • On multivariate analysis skin involvement at initial diagnosis was identified as a predictive factor for CNS recurrence in patients without CNS involvement at diagnosis (hazard ratio, 5.27; 95% confidence interval, 1.59-17.4; P = 0.007).
  • Survival rate after CNS recurrence at 2 years was 12% in patients without CNS involvement at diagnosis.
  • Central nervous system recurrence is a serious complication in IVLBCL patients and optimal strategies for CNS involvement should be established to obtain further improvements to clinical outcomes in the rituximab era.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Retrospective Studies. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20412122.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


36. Lal A, Bhurgri Y, Vaziri I, Rizvi NB, Sadaf A, Sartajuddin S, Islam M, Kumar P, Adil S, Kakepoto GN, Masood N, Khurshed M, Alidina A: Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas. Asian Pac J Cancer Prev; 2008 Jul-Sep;9(3):453-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extra nodal sites (EN-NHL) 235 (42%) cases included gastro-intestinal tract (44%), upper aerodigestive tract (19%), bones (8%), spine (5%), and unusual sites less than 3% each as breast, CNS, testis, lungs and skin.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Analysis of Variance. Biopsy, Needle. Cohort Studies. Confidence Intervals. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Odds Ratio. Pakistan. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004134.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


37. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK: Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer; 2010 Jan 15;116(2):424-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One treatment-related death occurred from myocardial infarction; 3 other grade 4 events occurred, including pulmonary embolism, neutropenia, and central nervous system (CNS) ischemia.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5748-54 [19001327.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):812-7 [10732751.001]
  • [Cites] Am J Med. 2000 Apr 15;108(6):487-95 [10781782.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Sep;44(9):2286-90 [10952569.001]
  • [Cites] Oncology (Williston Park). 2001 Jul;15(7):867-74; discussion 877-9 [11499688.001]
  • [Cites] N Engl J Med. 2001 Oct 18;345(16):1214-5 [11642248.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2736-44 [11675346.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2610-5 [12039921.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]
  • [Cites] J Exp Med. 2002 Aug 5;196(3):379-87 [12163566.001]
  • [Cites] Nature. 2002 Dec 5;420(6915):502-7 [12466842.001]
  • [Cites] Nat Rev Immunol. 2003 Mar;3(3):189-98 [12658267.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2551-7 [12829675.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2551-9 [12855630.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3351-6 [12947072.001]
  • [Cites] Clin Exp Immunol. 1995 Feb;99(2):160-7 [7851006.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1885-92 [9607928.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):380-6 [10384139.001]
  • [Cites] Melanoma Res. 2004 Dec;14(6):527-31 [15577325.001]
  • [Cites] Methods Mol Biol. 2005;302:237-52 [15937356.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2385-91 [17438097.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):527-34 [18235113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12643-4 [18753635.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • (PMID = 19918923.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / U10 CA032102-30; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / CA76426; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / U10 CA074647; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / K24 CA097588; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / CA032102-30; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ NIHMS151995; NLM/ PMC2811758
  •  go-up   go-down


38. Yamamoto T, Tsuji S: [Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis]. Brain Nerve; 2010 Aug;62(8):838-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The corresponding antigen, Ma2 is selectively expressed intracellularly in neurons and tumors as is the case with other onconeuronal antigens targeted by classical antibodies.
  • Some patients develop mesodiencephalic encephalitis with minor involvement of the limbic system, and some may manifest severe hypokinesis.
  • While it can cause severe neurological deficits or death in a substantial proportion of the patients, approximately one-third show neurological improvement and another 20 - 40% stabilize in response to treatment, including immunotherapy and/or tumor treatment.
  • Patients who have limited CNS involvement and testicular tumors with complete response to therapy are more likely to show neurological improvement.
  • In this respect, it is useful to highlight that anti-Ma2 encephalitis is almost always associated with testicular germ cell tumors in men younger than 50 years.
  • We experienced a 40-year-old patient with severe hypokinesis caused by anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes.
  • [MeSH-major] Antigens, Neoplasm / immunology. Autoantibodies. Limbic Encephalitis. Nerve Tissue Proteins / immunology
  • [MeSH-minor] Adult. Animals. Biomarkers / blood. Biomarkers / cerebrospinal fluid. Carcinoma, Non-Small-Cell Lung. Diagnosis, Differential. Female. Humans. Lung Neoplasms. Male. Middle Aged. Neoplasms, Germ Cell and Embryonal. Prognosis. Testicular Neoplasms

  • Genetic Alliance. consumer health - Limbic encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714032.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers; 0 / Ma2 antigen; 0 / Nerve Tissue Proteins
  •  go-up   go-down


39. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB, Children's Oncology Group: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol; 2005 May 20;23(15):3376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We performed a phase II study with patients stratified as follows: stratum 1: > or = 25% bone marrow blasts in first relapse; stratum 2: > or = 25% bone marrow blasts in > or = second relapse; stratum 3: positive CSF; stratum 4: extramedullary (non-CNS) relapse.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Infusions, Intravenous. Male. Maximum Tolerated Dose. Neoplasm Staging. Recurrence. Risk Assessment. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908649.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  •  go-up   go-down


40. Cao YB, Wang SS, Huang HQ, Xu GC, He YJ, Guan ZZ, Lin TY: [Primary breast lymphoma--a report of 27 cases with literature review]. Ai Zheng; 2007 Jan;26(1):84-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 27 patients, 26 were women and 1 was man, with the age ranged from 12 to 84; 18 were at stage IE, 6 at stage IIE, and 3 at stage III/IVE; according to the WHO 2001 lymphoma classification system, 22 had B-cell lymphoma (including 17 cases of diffuse large B-cell lymphoma, 2 cases of mucosa-associated lymphoid tissue lymphoma, 1 case of marginal zone lymphoma, and 2 cases of unclassified B-cell lymphoma), 3 had peripheral T-cell lymphoma, and 2 had unclassified lymphoma.
  • Sixteen patients had tumor relapse during the follow-up in the homolateral breast (6 cases), controlateral breast (4 cases), central nerve system (CNS) (3 cases), bone marrow (1 case), and lymph nodes (2 cases).
  • PBL tends to relapse to CNS, therefore, CT or MR image of CNS is necessary during follow-up.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms, Male / therapy. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Mastectomy / methods. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222374.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 14
  •  go-up   go-down


41. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM: Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol; 2010 Feb 20;28(6):1038-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE Adult post-transplantation lymphoproliferative disease (PTLD) has a reported 3-year overall survival (OS) of 35% to 40%.
  • On multivariate regression analysis, three factors were associated with progression and survival: CNS involvement (PFS, 4.70; P = .01; OS, 3.61; P = .04), bone marrow involvement (PFS, 2.95; P = .03; OS, 3.14; P = .03), and hypoalbuminemia (PFS, 2.96; P = .05; OS, 3.64; P = .04).

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2006 Jan 27;81(2):175-80 [16436959.001]
  • [Cites] Transplantation. 2002 Oct 27;74(8):1095-102 [12438953.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Lancet. 1993 Dec 18-25;342(8886-8887):1514-6 [7902900.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):214-21 [7779838.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3333-40 [7579436.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2052-9 [9626203.001]
  • [Cites] Lancet. 1998 Sep 5;352(9130):789 [9737292.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):191-6 [15621801.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):775-80 [15760401.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Transplantation. 2005 Jul 27;80(2):193-7 [16041263.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1661-7 [16149091.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7574-82 [16186599.001]
  • [Cites] Am J Transplant. 2005 Dec;5(12):2901-6 [16303003.001]
  • [Cites] Transplantation. 2005 Nov 15;80(9):1233-43 [16314791.001]
  • [Cites] Transplantation. 2005 Dec 27;80(12):1692-8 [16378063.001]
  • [Cites] Lancet. 2006 Jan 21;367(9506):233-9 [16427492.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):222-30 [14974943.001]
  • [Cites] Am J Transplant. 2006 Mar;6(3):569-76 [16468968.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3053-7 [16254143.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Transplantation. 2006 Aug 15;82(3):375-81 [16906036.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Haematologica. 2007 Feb;92(2):273-4 [17296588.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4648-56 [17925562.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4902-8 [17971586.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1489-94 [18024397.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1738-44 [18798108.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3186-91 [18846563.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3354-62 [19451438.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):375-85 [10716151.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3622-32 [11054435.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):772-8 [11157030.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1076-88 [11374406.001]
  • [Cites] Recent Results Cancer Res. 2002;159:67-80 [11785846.001]
  • [Cites] Haematologica. 2002 Jan;87(1):67-77 [11801467.001]
  • [CommentIn] J Clin Oncol. 2010 Jul 20;28(21):e366; author reply e367-8 [20479392.001]
  • [CommentIn] Nat Rev Clin Oncol. 2010 May;7(5):240 [20432523.001]
  • (PMID = 20085936.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109613-05; United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / K23 CA109613-A1; United States / NCI NIH HHS / CA / K23 CA109613-05; United States / NCI NIH HHS / CA / K23 CA109613-04; United States / NCI NIH HHS / CA / CA109613-04
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2834429
  •  go-up   go-down


42. Fischer L, Martus P, Weller M, Klasen HA, Rohden B, Röth A, Storek B, Hummel M, Nägele T, Thiel E, Korfel A: Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology; 2008 Sep 30;71(14):1102-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients.
  • BACKGROUND: The impact of meningeal dissemination in primary CNS lymphoma (PCNSL) is debated, and the reported frequency varies.
  • CONCLUSIONS: We found a low rate of meningeal dissemination in primary CNS lymphoma in this large prospective study.
  • [MeSH-major] Lymphoma / diagnosis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Neoplasm Metastasis / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Cell Count / statistics & numerical data. Combined Modality Therapy. Cytological Techniques / statistics & numerical data. Female. Humans. Immunoglobulin Heavy Chains / analysis. Immunoglobulin Heavy Chains / blood. Magnetic Resonance Imaging / statistics & numerical data. Male. Meninges / pathology. Middle Aged. Polymerase Chain Reaction / statistics & numerical data. Predictive Value of Tests. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824675.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


43. Hosono A, Makimoto A, Kawai A, Takaue Y: Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors. Bone Marrow Transplant; 2008 Jun;41(12):1067-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Graft vs Tumor Effect. Hematopoietic Stem Cell Transplantation / methods. Neoplasm Recurrence, Local / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adult. Female. Humans. Siblings. Transplantation, Homologous

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18332914.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


44. Ali Y, Rahme R, Moussa R, Abadjian G, Menassa-Moussa L, Samaha E: Multifocal meningeal melanocytoma: a new pathological entity or the result of leptomeningeal seeding? J Neurosurg; 2009 Sep;111(3):488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal melanocytoma is a rare benign CNS tumor derived from the leptomeningeal melanocytes.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle. Melanocytes / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Neoplasm Seeding. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361258.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol; 2009 Jan 20;27(3):385-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.
  • PURPOSE: Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months.
  • Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT.
  • Gross total resection of the primary tumor was achieved in 11 patients.
  • CONCLUSION: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
  • [MeSH-major] Brain Neoplasms / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Infratentorial Neoplasms. Prognosis. Prospective Studies. Supratentorial Neoplasms. Young Adult


46. Bariakh EA, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Obukhova TN, Magomedova AU, Vorob'ev AI: [Clinical and epidemiological features of Burkitt's lymphoma]. Ter Arkh; 2009;81(7):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To characterize clinical and epidemiological features of adult Berkitt's lymphoma (BL).
  • Bone marrow involvement was diagnosed in 22 (31%) patients, CNS was affected in 17 (24%) patients, of them 14 were males.
  • Fifty two (72%) patients had abdominal, retroperitoneal and/or small pelvis tumors.
  • Intestinal, hepatic, renal and gastric tumors occurred most frequently.
  • Specific ascitis was detected in 25 (48%), tumor pleuritis--in 11 (15%) patients.
  • Seven patients had concomitant involvement of the CNS.
  • Eight (38%) and 2 (10%) women had tumors of the ovaries and uterus, respectively.
  • CONCLUSION: BL is characterized by the following clinical features: young age of the patients, most of them are males, B-symptoms, short history, generalized stages, extranodal lesions, firequent involvement of the bone marrow and CNS.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Female. Humans. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Neoplasm Staging. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708573.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


47. Lee SH, Park J, Hwang SK: Isolated recurrence of intracerebral granulocytic sarcoma in acute lymphoblastic leukemia: a case report. J Neurooncol; 2006 Oct;80(1):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain magnetic resonance imaging demonstrated an enhanced mass which was initially interpreted as an extraaxial tumor in the right temporal region.
  • The biopsy result indicated that intraaxial lymphoblastic leukemia infiltration had caused CNS relapse.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Headache / etiology. Humans. Intracranial Hypertension / etiology. Intracranial Hypertension / surgery. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Ventriculoperitoneal Shunt. Vision Disorders / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] Radiology. 1986 Jul;160(1):223-5 [3459211.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Acta Haematol. 1998;99(4):231-3 [9644303.001]
  • [Cites] Cancer. 1973 Mar;31(3):520-33 [4511909.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] J Comput Assist Tomogr. 1987 Nov-Dec;11(6):938-41 [3500192.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Sep;17(8):1592-4 [8883663.001]
  • [Cites] Jpn J Clin Oncol. 1999 Apr;29(4):214-8 [10340046.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):31-5 [12416543.001]
  • [Cites] Bone Marrow Transplant. 1996 Sep;18(3):663-4 [8879638.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12 (2):259-62 [1902023.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):167-80 [9696368.001]
  • [Cites] Clin Neurol Neurosurg. 1986;88(2):135-9 [3463444.001]
  • [Cites] J Comput Assist Tomogr. 1979 Apr;3(2):226-33 [285087.001]
  • [Cites] Neurology. 1982 Jan;32(1):77-80 [6948173.001]
  • (PMID = 16645713.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Chen Z, Adamson PC, Children's Oncology Group: A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Mar;50(3):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
  • BACKGROUND: Rebeccamycin Analogue (NSC #655649), a chemically synthesized glycosyl-dichloro-indolocarbazole derivative of rebeccamycin with topoisomerase inhibiting activity, has in vitro activity against pediatric tumor cell lines and tumor specimens including rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma and medulloblastoma.
  • PROCEDURE: The primary objective of this trial was to determine the response rate to Rebeccamycin analogue NSC #655649 in children with refractory solid and CNS tumors.
  • With a global response rate of 3% observed in children with relapsed CNS and non-CNS solid tumors, further development of Rebeccamycin analogue in pediatric solid tumors is not recommended.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Diseases / chemically induced. Carbazoles. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug-Induced Liver Injury / etiology. Female. Glucosides. Humans. Infant. Infant, Newborn. Infusions, Intravenous. Male. Neoplasm Proteins / antagonists & inhibitors. Pancreatitis / chemically induced. Rhabdomyosarcoma / drug therapy. Salvage Therapy. Topoisomerase II Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17610262.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / P30CA-54174
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibiotics, Antineoplastic; 0 / Carbazoles; 0 / Glucosides; 0 / Neoplasm Proteins; 0 / Topoisomerase II Inhibitors; A60X6MBU6G / becatecarin
  •  go-up   go-down


49. Vestermark LW, Larsen S, Lindeløv B, Bastholt L: A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol; 2008;47(8):1526-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Brain metastases develop in nearly half of the patients with advanced melanoma and in 15 to 20% of these patients CNS is the first site of relapse.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Brain Neoplasms / drug therapy. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607876.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


50. Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crinò L: Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist; 2007 Jul;12(7):766-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
  • BACKGROUND: A higher incidence of central nervous system (CNS) metastases in HER-2-positive metastatic breast cancer (MBC) has recently been reported.
  • MATERIALS AND METHODS: Aims of this observational study were to evaluate the incidence of CNS metastases in HER-2-positive MBC patients, to define the outcome of patients with CNS metastases, and to identify the risk factors for CNS relapse.
  • At a median follow-up of 28 months from the occurrence of metastatic disease, 43 patients (35.2%) developed CNS metastases.
  • The median time to death from the diagnosis of CNS metastases was 23.46 months.
  • At multivariate analysis we found that only premenopausal status at diagnosis of breast cancer and visceral metastases as the dominant site at relapse were significantly associated with a higher risk for CNS metastases.
  • CONCLUSION: The CNS metastasis incidence is very high in HER-2-positive MBC, but the survival after CNS relapse in these patients is longer than in patients unselected for HER-2 status, because of the better control of extracranial disease obtained by trastuzumab.
  • The identified risk factors for CNS relapse could allow us to select a subgroup of HER-2-positive MBC patients as candidates for active surveillance for CNS progression (by computed tomography or magnetic resonance imaging) and/or as candidates for accrual in trials of prevention of CNS relapse.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Central Nervous System Neoplasms / drug therapy. Genes, erbB-2 / drug effects
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Disease Progression. Female. Humans. Incidence. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / genetics. Regression Analysis. Retrospective Studies. Risk Factors. Survival Analysis. Trastuzumab. Treatment Outcome


51. Rousseau A, Kujas M, Bergemer-Fouquet AM, van Effenterre R, Hauw JJ: Survivin expression in ganglioglioma. J Neurooncol; 2006 Apr;77(2):153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliogliomas are unusual central nervous system (CNS) neoplasms occurring mainly in children and young adults and inducing chronic pharmacoresistant epilepsy.
  • These are usually well differentiated neuroepithelial tumors composed of neurons in association with neoplastic glial cells.
  • Ten lesions were low-grade neoplasms whereas 5 were high-grade tumors.
  • Two additional tumors expressed survivin upon relapse.
  • Extended lifespan in survivin expressing cells might enhance aggressive behavior in these tumors through accumulation of mutations, thereby allowing progression to malignant phenotypes.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Ganglioglioma / metabolism. Ganglioglioma / pathology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Infant. Inhibitor of Apoptosis Proteins. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jul 1;101(1):146-55 [15222000.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1921-5 [10961895.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):173-83 [12241112.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1038-43 [9588548.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):513-20 [7541447.001]
  • [Cites] J Neurooncol. 2005 May;72(3):231-8 [15937645.001]
  • [Cites] Gut. 2000 May;46(5):645-50 [10764707.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):138-42 [11453385.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):989-1003 [9041162.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7494-506 [15326475.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):1994-2007 [15688031.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):1055-9 [8847572.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2229-37 [15512811.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jul;61(7):575-84 [12125736.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):360-8; discussion 368-9 [10825522.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):43-9 [9422522.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1497-502 [7798980.001]
  • [Cites] J Neurooncol. 2005 May;72(3):203-8 [15937641.001]
  • [Cites] Epilepsia. 1993 Jul-Aug;34(4):609-15 [8330569.001]
  • [Cites] Pediatr Neurosurg. 1992;18(5-6):310-4 [1476942.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):359-65 [15655550.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1757-65 [11337373.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2100-4 [10561264.001]
  • [Cites] J Neurooncol. 2002 Mar;57(1):59-66 [12125968.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):859-66 [8246054.001]
  • [Cites] Jpn J Cancer Res. 2000 Nov;91(11):1204-9 [11092988.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):127-31 [8988736.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):867-73 [8246055.001]
  • [Cites] Acta Neuropathol. 1994;88(2):166-73 [7985497.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):127-34 [10656440.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):305-10 [11352303.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):565-71 [9250169.001]
  • [Cites] Ann Pathol. 2001 Feb;21(1):55-8 [11223561.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):557-64 [9856655.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):46-54 [12509766.001]
  • (PMID = 16292482.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


52. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA: Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol; 2005 Apr;7(2):177-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
  • We determined the maximum tolerated dose (MTD), toxicity profile, pharmacokinetic parameters, and preliminary efficacy data of oral sodium phenylbutyrate (PB) in patients with recurrent malignant gliomas.
  • Twenty-three patients with supratentorial recurrent malignant gliomas were enrolled on this dose escalation trial.
  • Four dose levels of PB were studied: 9, 18, 27, and 36 g/day.
  • Data were collected to assess toxicity, response, survival, and pharmacokinetics.
  • All PB doses of 9, 18, and 27 g/day were well tolerated.
  • At 36 g/day, two of four patients developed dose-limiting grade 3 fatigue and somnolence.
  • At the MTD of 27 g/day, one of seven patients developed reversible grade 3 somnolence.
  • Median survival from time of study entry was 5.4 months.
  • One patient had a complete response for five years, and no partial responses were noted, which yielded an overall response rate of 5%.
  • Plasma concentrations of 706, 818, 1225, and 1605 muM were achieved with doses of 9, 18, 27, and 36 g/day, respectively.
  • The mean value for PB clearance in this patient population was 22 liters/h, which is significantly higher than the 16 liters/h reported in patients with other malignancies who were not receiving P450 enzyme-inducing anticonvulsant drugs (P = 0.038).
  • This study defines the MTD and recommended phase 2 dose of PB at 27 g/day for heavily pretreated patients with recurrent gliomas.
  • The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2292-300 [11489804.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):984-90 [10071293.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):239-42 [12241121.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1990;11:303-20 [2223397.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2288-95 [8486788.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):891-5 [8313377.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):507-14 [7829265.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):379-87 [9816181.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1755-62 [9815560.001]
  • [Cites] Mayo Clin Proc. 1999 Feb;74(2):137-45 [10069350.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3047-55 [11595694.001]
  • (PMID = 15831235.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01 CA 62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Phenylbutyrates; 9035-51-2 / Cytochrome P-450 Enzyme System
  • [Other-IDs] NLM/ PMC1871887
  •  go-up   go-down


53. Küker W, Nägele T, Thiel E, Weller M, Herrlinger U: Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology; 2005 Oct 11;65(7):1129-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
  • The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL).
  • Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / standards. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Contrast Media. Disease Progression. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2006 Apr 25;66(8):1287; author reply 1287 [16636266.001]
  • (PMID = 16217075.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  •  go-up   go-down


54. Ryan GF, Roos DR, Seymour JF: Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma; 2006 Jan;6(4):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The actuarial rate of central nervous system (CNS) recurrence at 8 years was 39% (+/- 14%), occurring only in patients with diffuse large-cell histology.
  • Targeted strategies such as CNS prophylaxis and contralateral breast irradiation might therefore improve prognosis and should be prospectively studied.
  • [MeSH-major] Breast Neoplasms / mortality. Lymphoma, B-Cell / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507213.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


55. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Goss B, Ford J: CNS germ cell tumors: pattern of failure and effects of radiation volume. J Med Assoc Thai; 2006 Apr;89(4):415-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS germ cell tumors: pattern of failure and effects of radiation volume.
  • This retrospective study was conducted to evaluate local control and overall survival after radiotherapy for patients with intracranial germ cell tumors and to investigate the influence of irradiated field on treatment outcome.
  • Thirty-two patients with surgically confirmed or suspected primary intracranial germ cell tumors (GCT) treated at the Division of Therapeutic Radiology and Oncology, Chiang Mai University, Chiang Mai, Thailand between January 1988 and December 1999 were reviewed Seven patients were not included in the analysis of treatment outcome and survival due to incompleteness of radiation treatment or death before the end of treatment.
  • Patients were irradiated to the primary tumor with an adequate margin in 7 patients, to the whole brain with a cone down boost in 8 patients.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local. Neoplasms, Germ Cell and Embryonal / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. Pinealoma / mortality. Pinealoma / radiotherapy. Retrospective Studies. Risk Factors. Survival Rate. Thailand / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16696383.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


56. Xiong NX, Zhao HY, Zhang FC, He ZQ: Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor. Neurosci Bull; 2007 Jan;23(1):41-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor.
  • OBJECTIVE: Nogo-A is an axon regeneration inhibitor, and its function in central nervous system (CNS) is still unknown.
  • The present study is to explore the relationship between the expression of Nogo-A and the malignancy of oligodendroglial tumors in patients.
  • METHODS: Tumor tissue samples with different malignancy grade were obtained from the hospitals.
  • The samples used for detection had been diagnosed as oligodendroglial tumors (oligodendroglioma or anaplastic oligodendroglioma).
  • The correlation test between the Nogo-A expression and the morphological changes (the percentages of atypical cells and mitotic cells in the tumors) related to the malignancy of tumor tissues was performed.
  • RESULTS: There was significant negative correlation between the Nogo-A expression and the morphological change of tumor tissues according to immunohistochemistry.
  • CONCLUSION: Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Myelin Proteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Down-Regulation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness / diagnosis. Nogo Proteins. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2002 May 1;22(9):3553-67 [11978832.001]
  • [Cites] J Neurosci. 2003 Jul 2;23 (13):5393-406 [12843238.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3929-36 [11494121.001]
  • [Cites] J Mol Neurosci. 2005;25(1):1-6 [15781961.001]
  • [Cites] J Cell Physiol. 2003 Aug;196 (2):312-8 [12811824.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):434-9 [10667796.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19280-5 [12639960.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):439-44 [10667797.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):149-58 [9426071.001]
  • [Cites] J Neurochem. 2004 Sep;90(5):1156-62 [15312170.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1390-9 [12618765.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5736-46 [11126360.001]
  • [Cites] Biochem J. 2005 Oct 15;391(Pt 2):433-40 [16095439.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2977-87 [15021917.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):5-9 [12510146.001]
  • (PMID = 17592524.001).
  • [ISSN] 1673-7067
  • [Journal-full-title] Neuroscience bulletin
  • [ISO-abbreviation] Neurosci Bull
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Myelin Proteins; 0 / Nogo Proteins; 0 / RTN4 protein, human
  •  go-up   go-down


57. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD, New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol; 2008 Aug;10(4):617-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were evaluated for response every 8 weeks and remained on the study until the tumor progressed or toxicities occurred.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Clin Pharmacol. 2000 Jun;49(6):562-73 [10848720.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Br J Clin Pharmacol. 2002 Apr;53(4):355-62 [11966665.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):986-1001 [12461520.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):679-89 [12586806.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2965-72 [12912943.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4406-11 [15240529.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]
  • [Cites] J Neurochem. 1994 Dec;63(6):2240-7 [7964744.001]
  • [Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-11 [8587429.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Feb;276(2):473-81 [8632312.001]
  • [Cites] Biochim Biophys Acta. 1996 May 28;1311(3):155-63 [8664342.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):784-90 [9504938.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Circulation. 1998 Nov 24;98(21):2262-8 [9826312.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 18477765.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062406; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA62406; United States / NCI NIH HHS / CA / UO1 CA-62475
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidines; V6D7VK2215 / atrasentan
  • [Other-IDs] NLM/ PMC2666236
  •  go-up   go-down


58. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


59. Yoshikata R, Yamamoto T, Kobayashi M, Ota H: Immunohistochemical characteristics of mature ovarian cystic teratomas in patients with postoperative recurrence. Int J Gynecol Pathol; 2006 Jan;25(1):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recurrence group was generally younger (mean, 22.9 +/- 1.26 vs. 32.8 +/- 1.15 years; p < 0.05), had higher tridermal components, and had greater central nervous system (CNS) component expression rate (9 vs. 48%, p < 0.05) compared with the non-recurrence group.
  • [MeSH-major] Neoplasm Recurrence, Local. Ovarian Neoplasms / chemistry. Teratoma / chemistry
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Female. Fluorescent Antibody Technique, Indirect. Glial Fibrillary Acidic Protein / analysis. Humans. Intermediate Filament Proteins / analysis. Nerve Tissue Proteins / analysis. Nestin. Neuroglia / pathology. Neurons / pathology. Synaptophysin / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306792.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Synaptophysin
  •  go-up   go-down


60. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, Thiel E: First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol; 2009 Aug;11(4):423-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
  • Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy.
  • Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Prognosis. Prospective Studies. Remission Induction. Survival Rate. Tissue Distribution. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Eur J Cancer. 1991;27(11):1356-61 [1835848.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Eur J Haematol. 2005 Apr;74(4):348-52 [15777348.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2528-34 [17932895.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1710-1 [15972281.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):53-8 [16283435.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Nov;7(3):236-8 [17229341.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):291-3 [17245621.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 19060176.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Other-IDs] NLM/ PMC2743222
  •  go-up   go-down


61. Millward MJ, Joshua A, Kefford R, Aamdal S, Thomson D, Hersey P, Toner G, Lynch K: Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Invest New Drugs; 2005 Jun;23(3):253-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Selected patients were offered participation in two sub-studies examining early changes in tumor metabolism with FDG-PET and changes in tumor polyamine content.
  • PATIENTS AND METHODS: Fifteen patients with measurable metastatic melanoma, normal cardiac function, and no known CNS metastases were eligible and received SAM486A by 1-hour IV infusion daily for 5 days every 3 weeks.
  • No patient had reduction of tumor metabolism.
  • [MeSH-minor] Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1983 Jan;1(1):52-65 [6230418.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2157-66 [12114416.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2045-52 [11956264.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1743-51 [9586887.001]
  • [Cites] Melanoma Res. 1995 Jun;5(3):147-54 [7640515.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):594-601 [10944598.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1736-43 [10815892.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3210-7 [8205541.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1299-305 [14977828.001]
  • [Cites] J Biol Chem. 1995 Feb 3;270(5):2124-32 [7836441.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • (PMID = 15868382.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amidines; 0 / Antineoplastic Agents; 0 / Indans; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 149400-88-4 / 4-amidinoindan-1-one 2'-amidinohydrazone; EC 4.1.1.50 / Adenosylmethionine Decarboxylase
  •  go-up   go-down


62. Kounin GK, Romansky KV, Traykov LD, Shotekov PM, Stoilova DZ: Primary spinal melanoma with bilateral papilledema. Clin Neurol Neurosurg; 2005 Oct;107(6):525-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis of primary CNS melanoma was made after dermatological and ophthalmological consultations, ruled out a metastatic lesion.
  • Primary leptomeningeal melanoma is an extremely rare spinal tumor.
  • [MeSH-major] Melanoma / diagnosis. Papilledema / etiology. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cerebrospinal Fluid / cytology. Cervical Vertebrae / pathology. Diagnosis, Differential. Erythrocyte Count. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Spinal Cord / pathology. Spinal Cord Compression / diagnosis. Spinal Cord Compression / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Papilledema.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202828.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports
  • [Publication-country] Netherlands
  •  go-up   go-down


63. Engelhard HH, Villano JL, Porter KR, Stewart AK, Barua M, Barker FG, Newton HB: Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. J Neurosurg Spine; 2010 Jul;13(1):67-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina.
  • OBJECT Patients having a primary tumor of the spinal cord, spinal meninges or cauda equina, are relatively rare.
  • Neurosurgeons encounter and treat such patients, and need to be aware of their clinical presentation, tumor types, treatment options, and potential complications.
  • The purpose of this paper is to report results from a series of 430 patients with primary intraspinal tumors, taken from a larger cohort of 9661 patients with primary tumors of the CNS.
  • METHODS Extensive information on individuals diagnosed (in the year 2000) as having a primary CNS neoplasm was prospectively collected in a Patient Care Evaluation Study conducted by the Commission on Cancer of the American College of Surgeons.
  • Intraspinal tumor cases were identified based on ICD-O-2 topography codes C70.1, C72.0, and C72.1.
  • RESULTS Patients with primary intraspinal tumors represented 4.5% of the CNS tumor group, and had a mean age of 49.3 years.
  • Pain was the most common presenting symptom, while the most common tumor types were meningioma (24.4%), ependymoma (23.7%), and schwannoma (21.2%).
  • [MeSH-major] Cauda Equina / pathology. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Peripheral Nervous System Neoplasms / pathology. Peripheral Nervous System Neoplasms / surgery. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Ependymoma / epidemiology. Ependymoma / pathology. Ependymoma / surgery. Female. Humans. Infant. Male. Meningioma / epidemiology. Meningioma / pathology. Meningioma / surgery. Middle Aged. Neurilemmoma / epidemiology. Neurilemmoma / pathology. Neurilemmoma / surgery. Postoperative Complications / epidemiology. Prospective Studies. Radiotherapy, Adjuvant. Registries. Risk Factors. Treatment Outcome. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594020.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, Copland JA, Tun HW: Selective central nervous system tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol; 2010;3(8):763-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective central nervous system tropism of primary central nervous system lymphoma.
  • Primary Central nervous system lymphoma (PCNSL) is most frequently a diffuse large B cell lymphoma (DLBCL), which is confined to the Central nervous system (CNS).
  • The lymphoma cells were shown to home to the CNS with histologic evaluations of the brain showing multiple large B cells in blood vessels consistent with intravascular large B cell lymphoma (IVL).
  • The findings are consistent with highly selective tropism of PCNSLforthe CNS and its vasculature.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Animals. Biomarkers, Tumor / metabolism. Brain / blood supply. Brain / pathology. Cell Movement. Fatal Outcome. Female. Humans. Lymphocytes / pathology. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation. Osteopontin / metabolism. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Brain. 2003 May;126(Pt 5):1058-67 [12690046.001]
  • [Cites] Pathol Int. 2004 Apr;54(4):231-6 [15028023.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1267-85 [17113462.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]
  • [Cites] Curr Oncol Rep. 2009 Jan;11(1):73-80 [19080745.001]
  • [Cites] Blood. 2009 Jan 1;113(1):266-7; author reply 267-8 [19122120.001]
  • (PMID = 21151389.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2993226
  • [Keywords] NOTNLM ; Lymphoma / central nervous system / tropism
  •  go-up   go-down


65. Pakasa NM, Pasquier B, Chambonnière ML, Morrison AL, Khaddage A, Perret AG, Dumollard JM, Barral FG, Péoc'h M: Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature. Virchows Arch; 2005 Jul;447(1):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature.
  • Central nervous system (CNS) solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms recognized less than a decade ago.
  • Approximately 60 cases of SFT have been reported in the central nervous system.
  • We describe three atypical SFTs of the CNS, two intracranial and one within the spine.
  • The intraspinal tumor occurred at T5-T7 in a patient with multiple café-au-lait spots, was predominantly myxoid and developed a second similar lesion at S3-S5 14 years later.
  • The MiB 1 index was lower in the second tumor.
  • These atypical presentations gave us an opportunity to provide further information about the natural histological course of CNS SFTs.
  • [MeSH-major] Brain Neoplasms / pathology. Fibroma / pathology. Sella Turcica / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Pathol Int. 2000 Oct;50(10):808-17 [11107053.001]
  • [Cites] Virchows Arch. 2004 May;444(5):459-64 [15014990.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):213-6; discussion 216-7 [14683560.001]
  • [Cites] J Neurosurg. 2004 Apr;100(4 Suppl Spine):358-63 [15070144.001]
  • [Cites] APMIS. 2000 Sep;108(9):617-25 [11110050.001]
  • [Cites] Histopathology. 1993 Mar;22(3):282-4 [8495961.001]
  • [Cites] J Neurosurg. 2000 Apr;92(2 Suppl):217-20 [10763696.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 May;44(5):249-54 [15200060.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Nov;131(1):69-73 [11734322.001]
  • [Cites] Pediatr Dev Pathol. 2001 May-Jun;4(3):267-75 [11370264.001]
  • [Cites] Neurosurgery. 2004 Apr;54(4):1004-9; discussion 1009 [15046670.001]
  • [Cites] J Neurosurg. 2000 Sep;93(3):490-3 [10969951.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):217-24 [8712177.001]
  • [Cites] Ann Pathol. 1999 Dec;19(6):532-5 [10617813.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):174-8; discussion 178-9 [14751636.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):182-5 [8805158.001]
  • [Cites] Neuroradiology. 1981 Mar;21(2):55-65 [6259553.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1330-42 [12360048.001]
  • [Cites] Neurosurg Rev. 2004 Oct;27(4):246-51 [15138847.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):57-69 [11763424.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):349-54 [11603810.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1354-60 [9351573.001]
  • [Cites] Ann Diagn Pathol. 2003 Jun;7(3):169-73 [12808569.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):217-21 [12232579.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):432-9 [12683870.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):160-4 [12127400.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):477-83 [9130996.001]
  • [Cites] J Neuroimaging. 2004 Jul;14(3):281-4 [15228772.001]
  • (PMID = 15926073.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


66. Giebel S, Krawczyk-Kuliś M, Adamczyk-Cioch M, Czyz A, Lech-Marańda E, Piatkowska-Jakubas B, Paluszewska M, Pałynyczko G, Piszcz J, Hołowiecki J, Polish Adult Leukemia Group: Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn; 2008 Jun;118(6):356-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
  • The central nervous system (CNS) is one of the most frequent extramedullary locations of adult acute lymphoblastic leukemia (ALL), affecting approximately 5% of patients at diagnosis.
  • In case of relapse, if no prophylaxis was administered, the rate of CNS involvement reaches 30-50%.
  • As the prognosis of patients with isolated or mixed CNS relapse is particularly poor, adequate prophylaxis seems critical.
  • The treatment comprises intrathecal cytostatics, cranial and spinal cord irradiation, as well as systemic chemotherapy including agents penetrating to the CNS.
  • This strategy allows a reduction in CNS relapses to less than 5% of cases.
  • Compliance to the prophylactic protocols should be one of the principles in the treatment of adult ALL.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / therapy. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619191.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 28
  •  go-up   go-down


67. Schrøder H, Kjeldstad M, Boesen AM, Nielsen OJ, Schmidt KG, Johnsen HE, Gregersen H, Gustafsson G: [Acute lymphoblastic leukaemia in Danish children and young people 10 to 19 years of age. Should young adults with acute lymphoblastic leukaemia be treated in the same way as children?]. Ugeskr Laeger; 2006 Jun 26;168(26-32):2554-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Data seem to indicate that young adults with acute lymphoblastic leukemia (ALL) have a better survival rate when treated with paediatric protocols than with adult ALL protocols.
  • RESULTS: There were no differences between the two groups with respect to the distribution of T-ALL, CNS leukemia, total WBC and high-risk chromosomal abnormalities.
  • CONCLUSION: Young adult patients with ALL might benefit from therapy with paediatric NOPHO ALL protocols.
  • [MeSH-minor] Adolescent. Adult. Child. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Prednisone / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Stem Cell Transplantation. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824410.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


68. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1988 May 14;1(8594):1065-7 [2896909.001]
  • [Cites] J Pathol. 2002 Jul;197(3):395-402 [12115887.001]
  • [Cites] Clin Microbiol Rev. 1999 Jul;12(3):367-82 [10398670.001]
  • [Cites] J Infect Dis. 2000 Nov;182(5):1321-5 [11023456.001]
  • [Cites] J Med Virol. 2005 Jan;75(1):76-85 [15543581.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1405-11 [14638964.001]
  • [Cites] J Med Virol. 2007 Jan;79(1):45-51 [17133548.001]
  • [Cites] J Virol. 2005 Aug;79(15):9439-48 [16014907.001]
  • [Cites] Pediatrics. 2008 Sep;122(3):513-20 [18762520.001]
  • [Cites] Mult Scler. 2004 Aug;10(4):355-9 [15327029.001]
  • [Cites] J Infect Dis. 2003 May 1;187(9):1377-87 [12717618.001]
  • [Cites] Curr Infect Dis Rep. 2008 Jul;10(4):292-9 [18765102.001]
  • [Cites] Curr Infect Dis Rep. 2004 Aug;6(4):316-321 [15265461.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1545-9 [10477678.001]
  • [Cites] PLoS One. 2008 Apr 30;3(4):e2028 [18446218.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):359-67 [9018122.001]
  • [Cites] Epilepsia. 2008 Nov;49(11):1828-37 [18627418.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(6):563-6 [17637686.001]
  • [Cites] Annu Rev Med. 2000;51:423-30 [10774474.001]
  • [Cites] New Microbiol. 1999 Oct;22(4):293-300 [10555198.001]
  • [Cites] J Neurosci. 2004 May 19;24(20):4875-83 [15152048.001]
  • [Cites] Mult Scler. 1999 Oct;5(5):355-62 [10516780.001]
  • [Cites] J Neurovirol. 2003 Oct;9(5):539-50 [13129768.001]
  • [Cites] J Neurol Sci. 1995 Dec;134(1-2):184-8 [8747864.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Neuro Oncol. 2008 Feb;10(1):10-8 [17951512.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):539-41 [18669440.001]
  • [Cites] J Child Neurol. 2007 Nov;22(11):1260-8 [18006954.001]
  • [Cites] J Neurovirol. 1998 Oct;4(5):486-94 [9839646.001]
  • [Cites] Acta Neuropathol. 2008 Jul;116(1):79-86 [18351367.001]
  • [Cites] Clin Diagn Virol. 1996 Jun;6(1):33-40 [15566888.001]
  • [Cites] Glia. 2006 Jun;53(8):789-98 [16541415.001]
  • [Cites] J Med Virol. 2008 Apr;80(4):689-93 [18297709.001]
  • [Cites] J Med Virol. 2004 Jul;73(3):465-73 [15170644.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • [Cites] J Neurol. 1997 Jul;244(7):450-4 [9266465.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):620-3 [10645234.001]
  • [Cites] J Clin Microbiol. 2008 Aug;46(8):2700-6 [18550745.001]
  • [Cites] J Med Virol. 2001 Jan;63(1):45-51 [11130886.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):838-43 [15578071.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Brain Res. 2008 Jul 24;1221:108-14 [18565499.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):217-45 [15653828.001]
  • [Cites] J Med Virol. 1995 Sep;47(1):105-11 [8551252.001]
  • [Cites] J Med Microbiol. 2003 Jan;52(Pt 1):5-18 [12488560.001]
  • [Cites] J Infect Dis. 2006 Apr 1;193(7):912-6 [16518751.001]
  • [Cites] J Infect Dis. 2007 Feb 1;195(3):450-4 [17205485.001]
  • [Cites] J Neurovirol. 2006 Apr;12(2):90-9 [16798670.001]
  • [Cites] PLoS Med. 2007 May;4(5):e180 [17535102.001]
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


69. Buda-Okreglak EM, Walden MJ, Brissette MD: Perineural CNS invasion in primary cutaneous follicular center lymphoma. J Clin Oncol; 2007 Oct 10;25(29):4684-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural CNS invasion in primary cutaneous follicular center lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / pathology. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Brain / pathology. Central Nervous System / pathology. Humans. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925565.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Rini BI, Weinberg V, Small EJ: A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer; 2005 Feb 1;103(3):553-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No central nervous system (CNS) toxicity was observed in three patients with CNS metastases.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Renal Cell / drug therapy. Deoxycytidine / analogs & derivatives. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Foot Dermatoses / chemically induced. Hand Dermatoses / chemically induced. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society
  • (PMID = 15612026.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R, Spitler LE: Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol; 2005 Dec 10;23(35):8992-9000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients (6%) developed CNS metastasis as the first site of disease progression, and 7 (23%) of 30 experienced CNS progression after receiving chemobiotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease Progression. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260693.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 85622-93-1 / temozolomide; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


72. Liang KL, Jiang RS, Lin JC, Chiu YJ, Shiao JY, Su MC, Hsin CH: Central nervous system infection in patients with postirradiated nasopharyngeal carcinoma: a case-controlled study. Am J Rhinol Allergy; 2009 Jul-Aug;23(4):417-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system infection in patients with postirradiated nasopharyngeal carcinoma: a case-controlled study.
  • BACKGROUND: It has been assumed that postirradiated nasopharyngeal carcinoma (NPC) patients are prone to central nervous system (CNS) infection.
  • METHODS: From September 1989 to May 2006, we conducted a retrospective study of 18 postirradiated NPC patients with CNS infection including brain abscess, cavernous sinus thrombosis, epidural abscess, and meningitis in our institute.
  • During the same period, 18 NPC patients without CNS infection who were matched for tumor stage, age, and gender with the study group were randomly selected from the cancer registry at our hospital and enrolled as the control group.
  • RESULTS: The local tumor relapse rate, nasopharyngeal radiotherapy dose, and skull base osteoradionecrosis were all significantly higher in patients with CNS infection (p = 0.003, 0.011, and 0.001, respectively).
  • Although the incidences of otitis media and chronic rhinosinusitis were higher in patients with CNS infection, there were no significant differences between the two groups (p = 0.469 and 0.568, respectively).
  • The in-hospital mortality was 61.1%, and the overall mortality of CNS infection was 83.3%.
  • CONCLUSIONS: Postirradiated NPC patients with skull base osteoradionecrosis are prone to have CNS infection.
  • CNS infection is an adverse prognostic factor in postirradiated NPC patients.
  • [MeSH-major] Carcinoma / radiotherapy. Central Nervous System / radiation effects. Central Nervous System Infections / etiology. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Biopsy. Dose-Response Relationship, Radiation. Endoscopy. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Taiwan / epidemiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671259.001).
  • [ISSN] 1945-8924
  • [Journal-full-title] American journal of rhinology & allergy
  • [ISO-abbreviation] Am J Rhinol Allergy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


73. Oechsle K, Kollmannsberger C, Honecker F, Boehlke I, Bokemeyer C: Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. Eur J Cancer; 2008 Aug;44(12):1663-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighty six percent responded to HD-CTX and 40% underwent CNS radiotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms. Neoplasms, Germ Cell and Embryonal. Testicular Neoplasms
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Clinical Trials, Phase II as Topic. Combined Modality Therapy / methods. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Multicenter Studies as Topic. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Salvage Therapy / methods. Stem Cell Transplantation. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2008 Aug;44(12):1622-4 [18653329.001]
  • (PMID = 18620855.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


74. Mariya Y, Sekizawa G, Matsuoka Y, Seki H, Sugawara T: Outcome of stereotactic radiosurgery for patients with non-small cell lung cancer metastatic to the brain. J Radiat Res; 2010;51(3):333-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cause of death was active extracranial disease, and central nervous system (CNS) failure was determined in 16%.
  • Chronic CNS toxicity of grade 4 was observed in 2 patients.
  • SRS alone allowing for salvage radiotherapy was effective for managing brain metastases and avoiding CNS failure from NSCLC.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Radiation Pneumonitis / prevention & control. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / pathology. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Salvage Therapy / methods. Treatment Outcome


75. Bayindir C, Mete O, Bilgic B: Retrospective study of 23 pathologically proven cases of central nervous system tuberculomas. Clin Neurol Neurosurg; 2006 Jun;108(4):353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of 23 pathologically proven cases of central nervous system tuberculomas.
  • INTRODUCTION: Extrapulmonary manifestations of tuberculosis involving the central nervous system (CNS) due to haematogenous spread are not a rare entity.
  • Tuberculoma is a granulomatous inflammatory process mimicking a neoplasm radiologically, so usually a biopsy is performed.
  • Histopathologic examination revealed granulomatous inflammation with central caseous necrosis in all patients.
  • DISCUSSION: Diagnosis of tuberculoma can be difficult, and in most of our cases, the clinical diagnosis was 'neoplasm'.
  • For this reason, clinicians must always be aware of it and consider it in the differential diagnosis of central nervous system mass lesions.
  • [MeSH-minor] Adolescent. Adult. Aged. Amphotericin B / therapeutic use. Anti-Infective Agents / therapeutic use. Child. Child, Preschool. Diagnosis, Differential. Female. Fever / diagnosis. Fever / epidemiology. Headache / diagnosis. Headache / epidemiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Necrosis / pathology. Retrospective Studies. Socioeconomic Factors

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644403.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


76. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH: High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood; 2005 Jan 15;105(2):496-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.
  • We assessed the cerebrospinal fluid (CSF) by flow cytometry and cytology in 51 newly diagnosed and 9 treated aggressive B-cell lymphomas at risk for central nervous system (CNS) involvement to examine the utility of flow cytometry, incidence of CSF disease, and clinical surrogates of CNS spread.
  • We hypothesize that the biologic phenotype associated with colonization of extranodal sites leads to CNS spread, possibly related to the microenvironment.
  • Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry.
  • [MeSH-major] Flow Cytometry / methods. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Incidence. Male. Middle Aged. Pathology, Clinical / methods. Prognosis. Recurrence. Risk Factors. Sensitivity and Specificity

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15358629.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Ohashi H, Kato C, Fukami S, Saito H, Hamaguchi M: Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases. Am J Hematol; 2005 Jun;79(2):142-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases.
  • We studied two cases with leukemia that relapsed in the central nervous system (CNS) after allogeneic stem cell transplantation.
  • These results seem to suggest that the graft-versus-leukemia effects might not be as effective in the CNS as in the BM, even when complete T-lymphoid chimerism is achieved.
  • [MeSH-major] Bone Marrow / pathology. Central Nervous System Neoplasms / therapy. Leukemia / therapy. Neoplasm Recurrence, Local. Peripheral Blood Stem Cell Transplantation. Tissue Donors. Transplantation Chimera
  • [MeSH-minor] Adult. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelomonocytic, Chronic / pathology. Leukemia, Myelomonocytic, Chronic / therapy. Male. Middle Aged. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929112.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Jahnke K, Hummel M, Korfel A, Burmeister T, Kiewe P, Klasen HA, Müller HH, Stein H, Thiel E: Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol; 2006 Oct 10;24(29):4754-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes.
  • PURPOSE: To search for subclinical systemic disease in bone marrow and peripheral blood in patients with primary CNS lymphoma (PCNSL) to elucidate whether extracerebral relapse may represent a sequel of initial occult systemic disease rather than true extracerebral spread.
  • RESULTS: Identical dominant PCR products were found in bone marrow aspirates, blood samples, and tumor biopsy specimens of two patients, indicating that the same tumor cell population is present in the CNS and in extracerebral sites.
  • An oligoclonal IgH rearrangement pattern was found in the tumor specimen of two other patients, whereas bone marrow and blood samples demonstrated the same dominant PCR products.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Brain Neoplasms / diagnosis. Immunoglobulin Heavy Chains / genetics. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / chemistry. Female. Gene Rearrangement. Humans. Male. Middle Aged. Neoplasm Staging / methods. Polymerase Chain Reaction. Recurrence

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


79. Abe T, Kitajima T, Honma K, Kurasaki T, Okazuka K, Shibasaki Y, Momoi A, Kuroha T, Masuko M, Yagisawa K, Furukawa T, Toba K, Aizawa Y: [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation]. Rinsho Ketsueki; 2008 Nov;49(11):1556-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initially, ALL relapsed in the central nervous system (CNS) 1 year after transplantation.
  • Then, ALL relapsed as a single bone tumor involving the CNS and pelvis 4 years after transplantation.
  • Finally, multiple bone tumors in the pelvis and lumbar bones were found as well as spread to the bone marrow 5 years after transplantation.
  • Flow cytometry analyses detected CD20-positive cells in the bone tumor.
  • Though the initial bone tumor was resistant to hyper CVAD, radiation was effective and this patient achieved complete remission.
  • After the third relapse, bone marrow achieved complete remission with the administration of pirarubicin, vincristine, prednisolone, and L-asparaginase (arranged DVP-L), though this combination chemotherapy itself was not effective in multiple bone tumors.
  • Thereafter, arranged DVP-L plus rituximab was administered, which resulted in significant tumor reduction.
  • Biweekly rituximab administration as maintenance therapy has completely prevented the regrowth of bone tumors.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Bone Marrow Transplantation. Bone Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047788.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


80. MacFadyen J, Savage K, Wienke D, Isacke CM: Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr Patterns; 2007 Jan;7(3):363-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development.
  • Finally, the fibroblast and pericyte expression of endosialin changes dynamically during development and becomes highly restricted in adult mouse tissues.
  • [MeSH-major] Antigens, CD / genetics. Central Nervous System / blood supply. Down-Regulation. Fibroblasts / metabolism. Gene Expression Regulation, Developmental. Neoplasm Proteins / genetics. Pericytes / metabolism


81. Wang ZH, Shi HY, Wang ZB: [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases]. Ai Zheng; 2009 Nov;28(11):1214-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases].
  • BACKGROUND AND OBJECTIVE: Metastatic alveolar soft tissue sarcoma (ASTS) of the central nervous system is rare and is easy to be misdiagnosed as other primary tumors of central nervous system.
  • This study was to analyze the clinical and pathological features of four patients with ASTS of the central nervous system and to clarify their differential diagnosis as well as prognosis.
  • The tumor cells had clear or eosinophilic cytoplasm and prominent nucleoli, arranged in alveolar structures, which were surrounded by delicate blood sinuses.
  • CONCLUSION: ASTS of the central nervous system was mostly metastatic and should be differentiated from other CNS tumors such as meningioma, melonocytic tumor, rhabdomyosarcoma and paraganglioma.
  • Metastatic ASTS of the central nervous system had poor prognosis and the five-year survival rate was low.
  • [MeSH-major] Cranial Fossa, Posterior. Sarcoma, Alveolar Soft Part / pathology. Sarcoma, Alveolar Soft Part / secondary. Skull Base Neoplasms / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Actins / metabolism. Adult. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasm Recurrence, Local. Paraganglioma / diagnosis. Prognosis. Rhabdomyosarcoma / diagnosis. S100 Proteins / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / S100 Proteins
  •  go-up   go-down


82. Herrlinger U, Hebart H, Kanz L, Dichgans J, Weller M: Relapse of primary CNS lymphoma after more than 10 years in complete remission. J Neurol; 2005 Nov;252(11):1409-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of primary CNS lymphoma after more than 10 years in complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Humans. Male. Methotrexate / therapeutic use. Procarbazine / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Jul 1;102(1):324-7 [12649152.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1745-53 [9164181.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1356-9 [6616403.001]
  • [Cites] Neurology. 2000 Apr 25;54(8):1707-8 [10762527.001]
  • [Cites] Ann Hematol. 2003 Nov;82(11):712-3 [12961033.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):626-32 [14628129.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1789-93 [12685833.001]
  • (PMID = 15895304.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


83. Mekni A, Kourda J, Chelly I, Ferchichi L, Bellil K, Hammouda KB, Kchir N, Zitouna M, Khaldi M, Haouet S: Hemangiopericytoma in the central nervous system. A study of eight cases. Neurochirurgie; 2008 Feb;54(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytoma in the central nervous system. A study of eight cases.
  • Most hemangiopericytomas (HPC) are located in the musculoskeletal system and the skin, while the location in the central nervous system (CNS) is rare.
  • The latter represents 2 to 4% in large series of meningeal tumors, thus accounting for less than 1% of all CNS tumors.
  • In the central nervous system, tumors with a hemangiopericytomatous histolopathological pattern can be either hemangiopericytomas or solitary fibrous tumors.
  • CNS-HPCs have a relentless tendency for local recurrence and metastases outside the CNS.
  • Metastasis can also appear many years after adequate treatment of the primary tumor.
  • We present a pathological study of eight patients with CNS-HPC and compare our results with corresponding published data.
  • The CNS-HPC group consisted of three males and five females with a mean age of 36.75 years.
  • The tumors were supratentorial in four cases, infratentorial in two cases, tentorial in one case and located in the spinal cord in the last one.
  • Histologically, CNS-HPCs were similar to their soft tissue counterparts.
  • Our study presents the pathological features of CNS-HPC as a distinct entity from both meningioma and solitary fibrous tumors.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Hemangiopericytoma / surgery
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. Female. Humans. Immunohistochemistry. Infratentorial Neoplasms / pathology. Infratentorial Neoplasms / surgery. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neuroglia / pathology. Neurosurgical Procedures. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308345.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


84. Glassmann A, Molly S, Surchev L, Nazwar TA, Holst M, Hartmann W, Baader SL, Oberdick J, Pietsch T, Schilling K: Developmental expression and differentiation-related neuron-specific splicing of metastasis suppressor 1 (Mtss1) in normal and transformed cerebellar cells. BMC Dev Biol; 2007;7:111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mtss1 encodes an actin-binding protein, dysregulated in a variety of tumors, that interacts with sonic hedgehog/Gli signaling in epidermal cells.
  • In the adult CNS, Mtss1 is found exclusively in cerebellar Purkinje cells.
  • Whereas immature granule cells express a Mtss1 variant observed also in peripheral tissues and comprising exon 12, this exon is replaced by a CNS-specific exon, 12a, in more mature granule cells and in adult Purkinje cells.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Cerebellum / growth & development. Gene Expression Regulation, Developmental. Microfilament Proteins / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Animals. Cerebellar Neoplasms / pathology. Exons. Humans. Mice. Mice, Inbred C57BL. Mice, Transgenic. Polymerase Chain Reaction. Protein Splicing / genetics. Purkinje Cells / pathology. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1996 Feb 29;379(6568):837-40 [8587609.001]
  • [Cites] Neuron. 1996 Mar;16(3):587-99 [8785056.001]
  • [Cites] Biotechniques. 1997 May;22(5):812-4 [9149852.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2085-8 [9187099.001]
  • [Cites] Int J Dev Neurosci. 1997 Oct;15(6):749-54 [9402225.001]
  • [Cites] DNA Res. 1997 Oct 31;4(5):307-13 [9455477.001]
  • [Cites] Brain Pathol. 1998 Jan;8(1):13-8 [9458162.001]
  • [Cites] Trends Neurosci. 1998 Sep;21(9):383-90 [9735946.001]
  • [Cites] J Immunol Methods. 1998 Jun 1;215(1-2):45-58 [9744747.001]
  • [Cites] Neuron. 1999 Jan;22(1):103-14 [10027293.001]
  • [Cites] Trends Biochem Sci. 1999 Jan;24(1):34-6 [10087920.001]
  • [Cites] Eur J Neurosci. 1999 Sep;11(9):3199-214 [10510184.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2724-9 [15545630.001]
  • [Cites] Dev Biol. 2005 Jan 15;277(2):366-77 [15617680.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):240-50 [15635447.001]
  • [Cites] J Neurosci. 2005 Jan 26;25(4):869-79 [15673667.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Sep 30;105(1-2):1-10 [12399102.001]
  • [Cites] Curr Opin Cell Biol. 2003 Feb;15(1):73-81 [12517707.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8452-9 [12482861.001]
  • [Cites] Am J Hum Genet. 2003 Apr;72(4):918-30 [12621583.001]
  • [Cites] Cerebellum. 2006;5(2):77-88 [16818382.001]
  • [Cites] Eur J Neurosci. 2006 Jul;24(2):466-78 [16903854.001]
  • [Cites] Cell. 2006 Oct 6;127(1):213-26 [17018287.001]
  • [Cites] J Biol Chem. 2006 Nov 17;281(46):35347-58 [17003044.001]
  • [Cites] Eur J Neurosci. 2006 Nov;24(9):2491-503 [17100838.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1337-47 [17115031.001]
  • [Cites] Mol Cell Neurosci. 2006 Dec;33(4):447-58 [17049261.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):168-76 [17151600.001]
  • [Cites] Structure. 2007 Feb;15(2):145-55 [17292833.001]
  • [Cites] J Biol Chem. 2007 Mar 9;282(10):7624-31 [17224454.001]
  • [Cites] J Cell Biol. 2007 Mar 26;176(7):953-64 [17371834.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2308-17 [17016438.001]
  • [Cites] Curr Biol. 2007 Jun 19;17(12):R455-7 [17580073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13438-43 [10557339.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] J Mol Biol. 2000 Apr 14;297(5):1183-94 [10764582.001]
  • [Cites] Trends Neurosci. 2000 Aug;23(8):372-6 [10906801.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):433-73 [12663865.001]
  • [Cites] Biochem J. 2003 Apr 15;371(Pt 2):463-71 [12570871.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3625-30 [12824381.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):453-63 [15684034.001]
  • [Cites] J Comp Neurol. 2005 Mar 14;483(3):318-28 [15682397.001]
  • [Cites] Nat Rev Neurosci. 2005 Mar;6(3):201-14 [15711600.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2059-66 [15688017.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1153-62 [15793295.001]
  • [Cites] Cell Mol Life Sci. 2005 May;62(9):955-70 [15868099.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1699-705 [15870888.001]
  • [Cites] Biochem J. 2005 Sep 15;390(Pt 3):641-53 [16134966.001]
  • [Cites] J Neurosci. 2005 Sep 14;25(37):8578-86 [16162939.001]
  • [Cites] J Cell Sci. 2005 Nov 15;118(Pt 22):5393-403 [16280553.001]
  • [Cites] Physiology (Bethesda). 2006 Feb;21:38-47 [16443821.001]
  • [Cites] Nat Methods. 2006 Mar;3(3):175-7 [16489333.001]
  • [Cites] PLoS Biol. 2006 Apr;4(4):e86 [16602821.001]
  • [Cites] Mol Cell. 2006 Jun 23;22(6):851-68 [16793553.001]
  • [Cites] Mol Biol Cell. 2006 Jul;17(7):3187-96 [16687575.001]
  • [Cites] J Neurosci. 2000 Aug 15;20(16):5899-905 [10934236.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):732-5 [11130076.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1001-4 [11163176.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Nat Neurosci. 2002 Mar;5(3):239-46 [11850630.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):58-66 [11911881.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):291-4 [12082544.001]
  • [Cites] Dev Genes Evol. 2002 Sep;212(8):403-6 [12203097.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:601-35 [12142283.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3635-41 [12824383.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3709-11 [12824399.001]
  • [Cites] J Neurosci Res. 2003 Aug 1;73(3):400-9 [12868073.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27981-7 [12695505.001]
  • [Cites] Cell. 2004 Jan 23;116(2):191-203 [14744431.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14929-36 [14752106.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Jun 21;150(2):177-90 [15158081.001]
  • [Cites] Nat Neurosci. 2004 Sep;7(9):923-9 [15286792.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):321-34 [15473970.001]
  • [Cites] Cancer Lett. 2004 Nov 25;215(2):209-20 [15488640.001]
  • [Cites] Protein Eng Des Sel. 2004 Jun;17(6):527-36 [15314210.001]
  • [Cites] Development. 2004 Nov;131(22):5581-90 [15496441.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):592-605 [4056828.001]
  • [Cites] Science. 1990 Apr 13;248(4952):223-6 [2109351.001]
  • [Cites] Neuroscience. 1993 Mar;53(1):121-30 [8097019.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8730-8 [7721778.001]
  • (PMID = 17925019.001).
  • [ISSN] 1471-213X
  • [Journal-full-title] BMC developmental biology
  • [ISO-abbreviation] BMC Dev. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Mtss1 protein, mouse; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2194783
  •  go-up   go-down


85. Sheedy SP, Welker KM, DeLone DR, Gilbertson JR: CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland. AJNR Am J Neuroradiol; 2006 Aug;27(7):1483-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland.
  • Pleomorphic adenomas (PAs), also known as benign mixed tumors, are common tumors of the parotid gland.
  • These tumors occasionally undergo malignant transformation, with potentially devastating consequences.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma, Pleomorphic / pathology. Brain Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908563.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Evens AM, Ziegler SL, Gupta R, Augustyniak C, Gordon LI, Mehta J: Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma; 2007 Jul;7(7):472-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
  • Human T-lymphotrophic virus-1-associated adult T-cell leukemia/lymphoma (ATLL) is a rare and often fatal disease.
  • This study reports on a 55-year-old man with relapsed/refractory leukemic-phase ATLL including significant central nervous system (CNS) disease with resistance to previous zidovudine/IFN and arsenic trioxide/IFN treatment.
  • The patient experienced a rapid hematologic and CNS clinical response with single-agent denileukin diftitox therapy (18 microg/kg per day for 5 days).
  • He tolerated 8 cycles of denileukin diftitox therapy well and experienced a sustained complete hematologic and CNS remission.
  • [MeSH-major] Bone Marrow Transplantation. Central Nervous System Neoplasms / therapy. Diphtheria Toxin / administration & dosage. Hematologic Neoplasms / therapy. Interleukin-2 / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arsenicals / administration & dosage. Drug Resistance, Neoplasm / drug effects. Humans. Interferons / administration & dosage. Male. Middle Aged. Oxides / administration & dosage. Recombinant Fusion Proteins / administration & dosage. Recurrence. Remission Induction. Transplantation, Homologous. Zidovudine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875237.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Oxides; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 4B9XT59T7S / Zidovudine; 9008-11-1 / Interferons; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


87. Lotze C, Schüler F, Krüger WH, Hirt C, Kirsch M, Vogelgesang S, Schmidt CA, Dölken G: Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study. Neuro Oncol; 2005 Oct;7(4):508-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study.
  • Relapse of peripheral non-Hodgkin's lymphoma (NHL) in the central nervous system commonly has a poor prognosis.
  • On day +83 after transplantation a CNS relapse of the lymphoma occurred.
  • [MeSH-major] Antibodies / therapeutic use. Brain Neoplasms / radiotherapy. Graft vs Leukemia Effect / physiology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antigens, CD20 / immunology. Humans. Male. Neoplasm Recurrence, Local / immunology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 2001;82:133-85 [11447762.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):843-6 [14520432.001]
  • [Cites] Blood. 2004 Jan 15;103(2):725-31 [12947008.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2208-16 [10498590.001]
  • [Cites] Bone Marrow Transplant. 1997 Sep;20(6):503-6 [9313885.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1178-84 [9454747.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):185-90 [10350348.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • (PMID = 16212815.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD20
  • [Other-IDs] NLM/ PMC1871735
  •  go-up   go-down


88. Neuhaus T, Ko Y, Muller RP, Grabenbauer GG, Hedde JP, Schueller H, Kocher M, Stier S, Fietkau R: A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer; 2009 Jan 27;100(2):291-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer.
  • A total of 320 patients with CNS-metastases due to SCLC or NSCLC were projected.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / therapy. Cranial Irradiation. Lung Neoplasms / therapy. Small Cell Lung Carcinoma / therapy. Topotecan / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Quality of Life. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Oncol. 2006;1:20 [16808850.001]
  • [Cites] Radiat Oncol. 2006;1:19 [16800900.001]
  • [Cites] Front Radiat Ther Oncol. 1999;33:354-63 [10549507.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3400-8 [11013281.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):59-67 [11249050.001]
  • [Cites] Forum (Genova). 2001 Jan-Mar;11(1):4-26 [11734861.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):367-74 [11818201.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1724-9 [12175688.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3644-50 [12202665.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):97-103 [12569292.001]
  • [Cites] Neurol Clin. 2003 Feb;21(1):1-23, vii [12690643.001]
  • [Cites] Oncologist. 2004;9(1):68-79 [14755016.001]
  • [Cites] J Neurosurg. 2004 May;100(5):842-7 [15137603.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1665-72 [15158627.001]
  • [Cites] Lung Cancer. 2004 Oct;46(1):107-11 [15364138.001]
  • [Cites] Br J Cancer. 1978 Dec;38(6):757-66 [369589.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Neurosurgery. 1991 Feb;28(2):201-5 [1997887.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):384-94 [7237407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(3):515-8 [1310495.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(3):195-202 [8529278.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):1-6 [8864997.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2090-6 [9164222.001]
  • [Cites] Ann Med. 1998 Jun;30(3):296-9 [9677016.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803 [10098435.001]
  • [Cites] Oncologist. 2004;9 Suppl 6:43-52 [15616149.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):185-91 [15629610.001]
  • [Cites] Strahlenther Onkol. 2005 Jan;181(1):20-5 [15660189.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD003869 [16856022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):839-44 [17379446.001]
  • (PMID = 19127261.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  • [Other-IDs] NLM/ PMC2634726
  •  go-up   go-down


89. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L: EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol; 2009 Apr;20(4):648-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In an attempt to identify markers of resistance to trastuzumab, we evaluated both the profiling of human epidermal growth factor receptor 2 (HER2)-positive tumor cells measuring the relative levels of EGFR, pMAPK, pAkt and PTEN and their correlations with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
  • PATIENTS AND METHODS: Tumor tissues for this retrospective analysis were available from 45 out of 76 patients with metastatic breast cancer treated from April 1999 to March 2006 with trastuzumab-based therapy at our Institution.
  • Evaluations of EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry (IHC) were carried out on all 45 tissue samples and their correlations with response to trastuzumab, incidence of central nervous system (CNS) metastases, time to progression (TTP), overall survival from diagnosis of breast cancer (OS1), from diagnosis of metastatic disease (OS2) and from the start of trastuzumab (OS3) were analyzed.
  • EGFR, pMAPK, pAkt and PTEN status by IHC were not significantly associated with response to trastuzumab, TTP, overall survival (OS1, OS2, OS3) and CNS metastases incidence.
  • It is likely that high expression of pMAPK (pMAPK-positive status) or pAkt (pAkt-positive status) could identify a subgroup of HER2-positive tumors with high activity of proliferation and survival pathways and with resistance to trastuzumab.
  • CONCLUSIONS: In HER2-positive metastatic breast cancers, EGFR, pMAPK, pAkt and PTEN status evaluated by IHC was not significantly associated with response to trastuzumab, TTP, OS and CNS metastases incidence.


90. Fassett DR, Pingree J, Kestle JR: The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg; 2005 Jan;102(1 Suppl):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature.
  • Myxopapillary ependymomas (MPEs) have historically been thought to be benign tumors occurring most frequently in adults.
  • Only 8 to 20% of these tumors occur in the first two decades of life, making this tumor a rarity in pediatric neurosurgery.
  • Four (80%) of these five patients suffered from disseminated disease of the central nervous system (CNS) at the time of presentation; this incidence is much higher than that reported in the combined adult and pediatric literature.
  • In nine cases (35%) CNS metastases occurred.
  • In those cases in which patients underwent screening for CNS tumor dissemination, however, the incidence of disseminated disease was 58% (seven of 12 patients).
  • In pediatric patients MPEs may spread throughout the CNS via cerebrospinal fluid pathways; therefore, MR imaging of the entire CNS axis is recommended at both presentation and follow-up review to detect tumor dissemination.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Ependymoma / secondary. Neoplasm Metastasis. Spinal Cord Neoplasms / pathology


91. Jalali R, Srinivas C, Nadkarni TD, Rajasekharan P: Suprasellar haemangiopericytoma--challenges in diagnosis and treatment. Acta Neurochir (Wien); 2008 Jan;150(1):67-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haemangiopericytomas of central nervous system (CNS) were first defined as a separate entity in 1942.
  • Previously they were either considered to be a histological variant of an angioblastic meningioma or a distinctive mesenchymal neoplasm.
  • [MeSH-major] Central Nervous System Cysts / diagnosis. Central Nervous System Cysts / therapy. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Sella Turcica
  • [MeSH-minor] Adult. Craniotomy. Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm, Residual. Pituitary Neoplasms / diagnosis. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176777.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 18
  •  go-up   go-down


92. Freeman BB 3rd, Daw NC, Geyer JR, Furman WL, Stewart CF: Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest; 2006 Apr-May;24(3):310-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.
  • EGFR expression has been noted in neuroblastoma and rhabdomyosarcoma cell lines and in tumor specimens from children with Wilms tumor, osteosarcoma, and glioma.
  • Thus, gefitinib, the first marketed EGFR tyrosine kinase inhibitor, was chosen for study in children with refractory solid tumors and central nervous system (CNS) malignancies.
  • This review discusses findings from 3 clinical trials of gefitinib in children with refractory solid tumors and CNS malignancies, focusing on the clinical pharmacology of the compound.
  • Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Child. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809160.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 67
  •  go-up   go-down


93. Svoboda M, Grell P, Simícková M, Fabian P, Petráková K, Palácová M, Macková D, Trojanec R, Hajdúch M, Pavlík T, Nenutil R, Vyzula R: [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors]. Klin Onkol; 2008;21(6):348-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical and laboratory factors, such as: patients conditions, character ofmetastatic spread, histology, estrogen, progesterone and Her-2 receptor status, Her-2/neu gene amplification, and serum tumor markers CEA, CA 15-3 and extracellular domain of Her-2 receptor (S-HER-2 ECD) were monitored.
  • CNS metastases occurred in 31 patients (27,7%).
  • CONCLUSIONS: We confirmed that the only one predictive marker for response to trastuzumab therapy is a proof of HER-2 tumor positivity.The highest prevalence of S-HER-2 ECD positivity among serum tumor markers and the strong association between initial and subsequent S-HER-2 ECD serum concentrations and time to progression and overall survival make the S-HER-2 ECD the most significant prognostic marker.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / analysis. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Receptor, ErbB-2 / analysis. Trastuzumab


94. Cooper PB, Auerbach A, Aguilera NS, Adair C, Moores L, Geyer D, Rushing EJ: Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature. Clin Neuropathol; 2006 Sep-Oct;25(5):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare primary CNS anaplastic large cell lymphoma in an immunocompetent adult: a clinical-pathologic case report and review case of the literature.
  • OBJECTIVE AND IMPORTANCE: Isolated anaplastic large cell lymphoma (ALCL) presenting in the primary central nervous system is distinctly uncommon.
  • The authors describe a case that clinically and radiographically simulated a primary glial neoplasm.
  • There appeared to be a clear demarcation between white matter and tumor with no obvious necrosis.
  • CONCLUSION: Reported in less than 20 patients, primary ALCL in an immunocompetent patient is rarely found intracranially; however, its ability to mimic glial neoplasms as well as other pathologies underlines its importance.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Combined Modality Therapy. Diagnosis, Differential. Glioma / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Radiotherapy. Seizures / etiology


95. Biswas S, Burke A, Cherian S, Williams D, Nicholson J, Horan G, Jefferies S, Williams M, Earl HM, Burnet NG, Hatcher H: Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation? Pediatr Blood Cancer; 2009 Jul;52(7):796-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation?
  • BACKGROUND: Supratentorial PNET (sPNET) are rare CNS tumors of embryonal origin arising in children and adults.
  • METHODS: Medical records were reviewed to gather demographic and clinical data about all embryonal CNS tumors in children and adults from 2001 to 2007.
  • Tumor pathology, clinical management and survival data were also assessed, particularly as regards those patients who received the Packer chemotherapy regimen for either sPNET or MB.
  • RESULTS: Eleven patients (five children and six adults) were identified with non-pineal sPNET, three children with pineal sPNET, and 19 patients (18 children and 1 adult) with MB.
  • There was no difference in overall survival (OS) rates between pediatric and adult sPNET.
  • We suggest that it is time to reconsider the use of this regimen in teenage and young adult non-pineal sPNET and to investigate the utility of alternative approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / therapy. Cranial Irradiation. Medulloblastoma / therapy. Neuroectodermal Tumors, Primitive / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Follow-Up Studies. Humans. Lomustine / administration & dosage. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19202566.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


96. Park DS, Chung MK, Chung JI, Ahn HJ, Lee ES, Choi HY, Yoon DK, Cheon J, Hong SJ, Lee YG, Yoon SM, Kim WJ, Kim HJ, Ryu SB, Ro JY: Histologic type, staging, and distribution of germ cell tumors in Korean adults. Urol Oncol; 2008 Nov-Dec;26(6):590-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic type, staging, and distribution of germ cell tumors in Korean adults.
  • OBJECTIVES: To investigate the presentation of germ cell tumors (GCT) in terms of histology and stage, to better clarify the epidemiology of this disease in eastern Asia.
  • Clinical parameters at the time of initial diagnosis were classified in terms of the American Joint Committee on Cancer (AJCC) tumor, nodes, metastasis staging (TNMS) system, the International Germ Cell Cancer Collaborative Classification (IGCCC), for high-risk stage I nonseminomatous GCT (NSGCT) of testis.
  • RESULTS: The anatomic distributions for the primary sites of the observed tumors were as follows: testis 471 cases (67%); central nervous system (CNS) 137 cases (20%); mediastinum 78 cases (11%), and retroperitoneum 12 cases (2%); 239 (51%) of 471 tumors with testicular primary were seminoma.
  • Of NSGCT of testis, 129 (58%), 73 (33%), and 21 (9%) of tumors presented with good, intermediate, and poor prognosis, respectively, based on IGCCC, whereas 231 (99%) patients were classified with a good prognosis and 3 (1%) with an intermediate prognosis amongst seminomas of testis; 193 (82%) cases presented as stage I testicular seminoma whereas 120 (54%) cases presented as stage I NSGCT.
  • NSGCT presents itself as a more aggressive form whereas seminoma is a very indolent tumor when compared with cases in Western countries.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Korea / epidemiology. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367106.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Reman O, Pigneux A, Huguet F, Vey N, Delannoy A, Fegueux N, de Botton S, Stamatoullas A, Tournilhac O, Buzyn A, Charrin C, Boucheix C, Gabert J, Lhéritier V, Vernant JP, Fière D, Dombret H, Thomas X, GET-LALA group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res; 2008 Nov;32(11):1741-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group.
  • Outcome of adult acute lymphoblastic leukemia (ALL) with central nervous system (CNS) involvement is not clearly defined.
  • We studied 104 patients presenting with CNS involvement at diagnosis among 1493 patients (7%) included into the LALA trials, and 109 patients presenting CNS disease at the time of first relapse among the 709 relapsing patients (15%).
  • Eighty-seven patients (84%) with CNS leukemia at diagnosis achieved complete remission (CR).
  • There were no significant differences in terms of CR, OS and DFS among patients with CNS involvement at diagnosis and those without CNS disease.
  • After a first relapse, 38 patients with CNS recurrence (35%) achieved a second CR.
  • Outcome was similar to that of relapsing patients without CNS disease.
  • CNS leukemia in adult ALL is uncommon at diagnosis as well as at the time of first relapse.
  • With intensification therapy, patients with CNS leukemia at diagnosis have a similar outcome than those who did not present with CNS involvement.
  • CNS leukemia at first relapse remains of similar poor prognosis than all other adult ALL in first relapse.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508120.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. Nieder C, Astner ST, Andratschke NH, Adam M: Disease presentation and outcome in very young patients with brain metastases from breast cancer. Tumori; 2008 Sep-Oct;94(5):691-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In patients with information available, tumors were poorly differentiated and metastatic to the axillary lymph nodes at primary diagnosis.
  • Whole-brain radiation therapy plus surgery or radiosurgery provided durable CNS control in most of the patients.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Breast Neoplasms / pathology. Breast Neoplasms / therapy
  • [MeSH-minor] Adult. Axilla. Cranial Irradiation. Female. Humans. Karnofsky Performance Status. Lymphatic Metastasis. Neoplasm Staging. Radiosurgery. Retrospective Studies. Treatment Outcome


99. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A: Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro Oncol; 2010 Apr;12(4):409-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of t